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chapter 1
Introduction and outline of the thesis
1.1 Background
Epidemiology
Hodgkin lymphoma (HL) is a relatively rare type of cancer. e incidence rate of HL
over the past decade in theNetherlands was .-. per . persons per year (Eu-
ropean standardized rate). e absolute annual incidence in the Netherlands in 
was , which accounts for approximately  of all newly diagnosed malignancies
(). Incidence of HL has remained stable. e majority of patients are younger than
 years of age, which makes HL the third most common form of cancer in young
adults. Response to treatment is generally good, leading to high disease-specific and
overall survival rates. Currently, -year overall survival rates for the total group of HL
patients are approximately . Survival is highest in patients presenting with early
stage disease, with -year overall survival rates of - (, ). Overall survival in
patients presenting with more advanced disease ranges from - (, ).
HL is a lympho-proliferative disorder of B-lymphocytes, and mainly affects pe-
ripheral lymph nodes. HL is subdivided in several histological subtypes. Classical HL,
consisting of nodular sclerosing,mixed cellularity, lymphocyte-rich and lymphocyte-
depleted subtypes, accounts for approximately  of new HL cases. e remaining
 is the nodular lymphocyte-predominant subtype. Little is known about the aetiol-
ogy of HL. A possible relation with Epstein-Barr infection (EBV) has been suggested
since EBV antigens have been detected in up to  of HL patients, especially in









Staging in HL is important, both for predicting prognosis as well as for selection of
optimal treatment. Staging occurs according to the Ann-Arbor classification system
(Table .), which reflects the number and spread of affected lymph node areas. It
also takes into account systemic symptoms due to the lymphoma such as weight loss,
night sweats or fever which are present in approximately  of HL patients (, ).
Approximately two thirds of patients present with early stage (stage I-II) disease.
Table 1.1: Ann-Arbor staging system for HL (9)
Stage I Involvement of a single lymph node region or extralymphatic region/organ (IE)
Stage II Involvement of 2 or more lymph node regions or lymphatic structures on the same side of the diaphragm alone or
extralymphatic regions on the same side of the diaphragm alone (IIE)
Stage III Involvement of lymph node regions on both sides of the diaphragm with localized extralymphatic (IIIE) or splenic (IIIS)
involvement or both (IIIES)
Stage IV Involvement of one or more organs or tissues outside the lymphatic system, with or without involvement of nearby
lymph nodes
A: Without B symptoms
B: Fever, night sweats, weight loss of >10% body weight over the last 6 months
Tailoring of therapy to prognostic risk factors such as stage of disease or pres-
ence of systemic symptoms has been investigated in the course of various clinical
trials. e subdivision of early stage disease in a favourable and an unfavourable risk
group, based on the presence of these prognostic factors had a significant impact on
progression-free survival and overall survival (). Although various HL study groups
have defined different sets of prognostic risk factors (Table .), all three of the cur-
Table 1.2: Risk factor definition in early stage (stage I-II) HL according to various study groups
GHSG EORTC NCCN




ESR ≥50 (A) or ≥30 (B) ESR ≥50 (A) or ≥30 (B) ESR ≥50 (A)
B-symptoms
≥3 nodal areas (out of 11 GHSG areas) ≥4 nodal areas (out of 5
supra-diaphragmatic EORTC areas)
≥4 nodal regions (out of 17 Ann Arbor
regions)
Patients are staged in the unfavourable risk group if at least one of the above listed factors is present. Within the GHSC system, patients
with a large mediastinal mass as well as ≥1 extranodal lesion are considered as advanced stage and treated in accordance with stage III-IV
HL (2). GHSG = German Hodgkin Study Group; EORTC = European Organisation for Research and Treatment of Cancer; NCCN =
National Comprehensive Cancer Network.
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rently defined classification systems are significantly related to outcome. Moreover,
the classification into favourable and unfavourable risk groups has led to risk-adapted
treatment strategies, in which patients presenting with unfavourable early stage dis-
ease receive more intensified treatment.
For patients presenting with advanced stage HL a different prognostic score is
used for risk stratification.emost widely used prognostic index is the International
Prognostic Score (IPS) which was developed based on outcome data of a large cohort
of HL patients with advanced stage disease, treated in accordance with different HL
study groups. e prognostic index contains seven clinical parameters, in which one
point is assigned to each of the following risk factors:
• Age ≥ years
• Male sex
• Stage IV disease
• Hemoglobin level < g/L
• White blood count >×/L
• Lymphocyte count <.×/L or < of differential
• Albumin level < g/L
With increasing IPS scores, both progression-free survival and overall survival de-
crease ().
Treatment
Over the past decades important improvements have been made in the treatment of
HL. e earliest treatment of HL consisted of radiation therapy. In the s ortho-
voltage (kilovoltage) radiation was used. Large radiotherapy fields were given but due
to the physical properties of this type of radiation, penetrating only to a depth of -
cm, outcomeswere disappointing (). After the introduction ofmegavolt irradiation
with at first Cobalt machines followed by linear accelerators in the s, deeper
lymph node areas were much better reached. Moreover, with megavoltage radiation
beams the dose distribution became more homogeneous. Consequently, with these
improved radiotherapy techniques, outcomes improved significantly and survival
rates of - were reached (). In the absence of effective systemic treatment
options, radiotherapy using large treatment volumes such as total nodal or subtotal
nodal fields was the only curative treatment option for HL patients and remained








have been treated within clinical studies designed to tailor treatment approaches to
risk factors and improve treatment outcome.
For patients with early stage disease, the European Organisation for Research
and Treatment of Cancer (EORTC) initiated a first clinical study for the treatment
of early stage HL in . After surgical staging, including splenectomy and lymph
node sampling, patients were randomized between radiation treatment alone, or
radiation treatment followed by chemotherapy (weekly vinblastine during  years
after completion of radiotherapy). is trial showed improved progression-free sur-
vival after combination therapy, but failed to show an improvement in overall sur-
vival, which was about  to  in both arms. Using the trial data a first ef-
fort was made in defining prognostic factors (). In the next decades subsequent
EORTC studies were conducted. Based on results of these studies it became clear
that clinical staging of patients with HL was sufficient for determination of treat-
ment, and surgical staging was abandoned, thus resulting in significant reduction
of morbidity due to staging splenectomy. With the introduction of more potent
multi-agent chemotherapy regimes in combination with radiotherapy, such as the
MOPP regime (mechlorethamine, vincristine, procarbazine and prednisone) and
MOPP-ABV (MOPP alternating with doxorubicin,bleomycin and vinblastine), clear
improvements of both disease-free survival as well as overall survival were demon-
strated. Survival now exceeded , although event-free survival rates were lower.
ese highly effective chemotherapy regimes came, however, at the cost of serious
side effects, such as infertility and (hematologic) secondary cancers (). Radiother-
apy therefore kept its prominent role in treatment, although an increasing number
of studies showed that the extent of the radiotherapy fields could be reduced. Field
sizes decreased from (sub)total nodal fields (all lymph node areas on both sides of the
diaphragm) to mantle fields (all lymph node areas above the diaphragm) to involved
fields (only treating the affected lymph node areas). It became increasingly evident
that favourable outcome results were maintained with the combined modality treat-
ment approach using these new chemotherapy regimes followed by involved-field
radiotherapy with a lower total radiation dose, and this approach became the new
standard of care ().
However, in due time it became clear that not only treatment with chemotherapy
but also treatment with radiotherapy led to an increased risk of potentially serious
long-term complications. ese complications are often not seen until - years
after completing radiation treatment, and risks do not subside over time (). e
first effort to omit radiotherapy completely from the treatment of patients with early
stage HL with a favourable prognosis was made in the EORTC H trial. Unfortu-
nately, a  reduced event-free survival was seen in patients who did not receive
radiotherapy. It has been suggested that this might, in part, be due to the less toxic,
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but potentially less effective EBVP (epirubicin, bleomycin, vinblastin and prednisone)
chemotherapy regime used in this study.
e recent H study investigated the possibility of treatment adaption in early
stage HL, based on chemotherapy response measured by interim fluordeoxyglucose
positron emission tomography scan (FDG-PET scan). Patients with favourable prog-
nostic features who had a negative FDG-PET after two courses of ABVD chemother-
apy were randomized between involved node radiotherapy or no further treatment.
is arm of the study was closed prematurely after an interim analysis showed an
increase in recurrent disease in patients who did not receive radiation therapy ().
Currently, there is no evidence that radiotherapy can be fully omitted from treatment
of HL patients with early stage disease without compromising at least progression-
free survival (, ).
e role of radiotherapy in the treatment of advanced stage HL has been limited
(). Key part of the treatment for advanced stage disease has been systemic treat-
ment. Over the past decades increasingly effective chemotherapy agents have been
tested. In a meta-analysis the role of additional radiation treatment was explored. An
increase in tumor control was demonstrated, however without an increase in overall
survival ().e EORTCH/ trial evaluated the role of radiotherapy after systemic
treatment, and showed no benefit of radiotherapy in patients in complete response
after chemotherapy. However, patients in partial response after systemic treatment
did benefit from involved field radiotherapy in terms of increased progression-free
and overall survival ().
1.2 Late treatment effects
Cure ofHLmay come at a cost. In the past decades it has become increasingly evident
that both radiotherapy and chemotherapy can cause numerous long-term adverse
effects. While the risk of of mortality due to HL abates with time, overall (all-cause)
survival of HL survivors continues to decrease at a higher rate compared to an age
matched normpopulation.is is due tomorbidity andmortality from late treatment
sequelae (Figure .)(, ). Radiation-induced late treatment effects progressively
increase from  to  years after initial treatment. Epidemiological studies have
shown that even after  years of follow-up the relative risks (RR) of developing late
treatment complications do not decline ().
Numerous late treatment sequelae have been described in epidemiological stud-







first treatment, because the AER of death from causes other than
HD increased dramatically throughout follow-up time. From 20
years since the start of treatment, the overall excess mortality
was completely attributable to the excess mortality from diseases
other than HD (Fig 3). According to the Kaplan-Meier method,
the 25-year overall survival rate was 56%. When treating all
second malignancies or all CVDs as censored, the proportion of
surviving patients at 25 years increased by 8.8% to 64.8% and by
4.2% to 60.2%, respectively.
As we expected, when the disease-specific survival for HD
was evaluated over time, the 20-year actuarial survival estimates
improved spectacularly, with rates of 65%, 77%, and 87% for
the treatment periods 1965 to 1972, 1973 to 1979, and 1980
to 1987, respectively.
Death From STs
Excess mortality from STs was mainly due to excess
mortality from cancers of the gastrointestinal (RR, 7.7; AER,
10.4) and respiratory tract (RR, 8.8; AER, 9.4). With increas-
ing age at start of treatment, the RR of death from STs
decreased (Table 3; P for trend ! .001). The risk of death
from STs was highest in patients younger than 35 years at the
end of follow-up. Patients from the salvage group were at
significantly elevated risk of death from STs (RR, 8.3; 95%
CI, 6.1 to 11.2), compared with patients receiving initial
treatment only (P " .04). The RR and AER of death from STs
increased considerably during the follow-up period, but the
RR appeared to level off after 20 years (P for trend " .02).
Table 4 shows the relative risks of ST death, according to age
at treatment and attained age. In each subgroup, according to
age at start of treatment, we observed trends of declining RRs
of mortality from STs as patients grew older.
Fig 3. Absolute excess mortality from various disease categories over time. HD,
Hodgkin’s disease; CVD, cardiovascular disease.
Table 3. Mortality From Second Malignancy by Sex, Age, Attained Age, Treatment, Treatment Period, and Follow-Up Interval
Cause of Death
Solid Tumors (n " 76) Leukemia and MDS (n " 15 # 9)
O E RR 95% CI AER* O E RR 95% CI AER*
Sex
Male 41 6.0 6.9 4.9 to 9.3 30.1 12 0.3 35.3 18.2 to 61.6 10.0
Female 35 5.5 6.3 4.4 to 8.8 30.5 12 0.2 49.8 25.7 to 86.9 12.2
Age at start of treatment
! 20 years 14 1.0 14.8 8.1 to 24.9 22.3 4 0.1 37.7 10.3 to 96.6 6.7
21-30 years 37 4.3 8.6 6.1 to 11.9 33.5 14 0.2 57.7 31.6 to 96.9 14.1
31-40 years 25 6.3 4.0 2.6 to 5.9 33.1 6 0.2 25.8 9.5 to 56.1 10.2
Attained age
! 35 years 5 0.1 36.9 12.0 to 86.2 20.8 15 0.04 372 208 to 613 64.0
36-45 years 24 0.8 30.4 19.5 to 45.2 45.2 4 0.1 44.0 12.0 to 113 7.6
46-55 years 34 4.5 7.6 5.2 to 10.6 32.2 5 0.2 21.1 6.8 to 49.2 5.2
" 56 years 13 6.1 2.1 1.1 to 3.6 14.8 0 0.2 0.0 0.0 to 17.3 $0.4
Treatment
Initial RT only 22 4.1 5.4 3.4 to 8.2 26.0 1 0.2 5.2 0.1 to 29.1 1.2
Initial RT # CT only 9 2.1 4.4 2.0 to 8.3 16.3 5 0.1 45.6 14.8 to 106 11.5
Salvage treatment 45 5.4 8.3 6.1 to 11.2 39.1 18 0.3 64.3 38.1 to 102 17.5
Treatment period
1965-1972 39 5.6 7.0 5.0 to 9.5 43.1 6 0.3 23.7 8.7 to 51.7 7.4
1973-1979 28 3.9 7.2 4.8 to 10.5 31.3 12 0.2 59.1 30.5 to 103 15.3
1980-1987 9 2.1 4.4 2.0 to 8.4 12.0 6 0.1 47.9 17.6 to 104 10.1
Follow-up interval
0-5 years 0 0.8 0.0 0.0 to 4.8 $1.4 4 0.1 34.4 9.4 to 88.0 6.8
6-10 years 5 1.2 4.1 1.3 to 9.6 7.8 14 0.1 137 75.0 to 230 28.7
11-15 years 11 2.0 5.4 2.7 to 9.7 20.7 4 0.1 36.8 10.0 to 94.2 9.0
16-20 years 22 2.6 8.6 5.4 to 13.0 59.4 2 0.1 19.6 2.4 to 70.8 5.8
21-25 years 18 2.5 7.3 4.3 to 11.6 79.4 0 0.1 0.0 0.0 to 46.0 $0.3
26-30 years 15 1.8 8.3 4.7 to 13.7 136.9 0 0.1 0.0 0.0 to 68.0 $0.6
% 30 years 5 0.7 7.6 2.5 to 17.8 191.8 0 0.02 0.0 0.0 to 208 $0.8
Abbreviations: MDS, myelodysplastic syndrome; O, observed number of deaths; E, expected number of deaths; RR, relative risk; AER, absolute excess risk; RT, radiotherapy;
CT, chemotherapy.
*Per 10,000 patients per year.
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Figure 1.1: Absolute excess mortality from various disease categories over time, from a cohort of 1261 HL
survivors. Mortality from HD decrease, while mortality due to solitary tumors and cardiovascular disease
increase over time (23). HD = Hodgkin disease, CVD = cardiovascular disease AER = absolute excess risk.
ies after treatment with chemotherapy, radiotherapy or a combination of these
modalities for HL (Figure .).
Secondary tumors
One of themost serious long-term complications of treatment forHL is the induction
of secondary ca cers. In the first ten years after treatment patients are mainly at risk
of developing secondary haematological cancers due to exposure to chemotherapy.
An increased risk of acute leukaemia and myelodysplastic syndrome was found in
patients treated with various chemotherapy regimes, especially after receiving alky-
lating agents (). e relative risk of secondary Non-Hodgkin lymphomas is also
significantly increased, both in patients treated with chemotherapy as well as after
treatment with radiotherapy (RR ,  CI -)(). From approximately  to 
years after treatment the risk of developing radiation-induced solid tumors increases.
Solid tumors account for the majority of second cancers in HL survivors. e most
common second malignancy is breast cancer in female HL survivors treated with
thoracic (mediastinal and/or axillary) radiotherapy. Compared to the general pop-
ulation, these patients have a -fold increased risk of breast cancer (). Risks are





















Figure 1.2: An overview of possible late treatment sequelae after treatment with chemotherapy, radiother-
apy or a combination of these modalities (24).
especially increased in patients treated before the age of , and especially before the
age of  (Figure .).
e volume of breast tissue covered by the radiation treatment fields (mantle
fields including mediastinal and axillary fields vs. only superior mediastinal fields)
also has a significant impact on the risk of developing breast cancer. Decreasing
radiation volumes lead to a reduction in risk of breast cancer (). It has been demon-
strated that survival is higher when breast cancer in female HL survivors is detected
in an early stage. For this reason, current follow-up guidelines for HL recommend
screening of female HL survivors at risk for developing radiation induced breast
cancer.
HL survivors are also at risk of developing several other types of solid tumors.
As with breast cancer, risks depends on age at treatment of HL, time since treat-
ment, location of radiation treatment fields and radiation dose. Risks of developing
lung cancer (especially in smokers), thyroid cancer, cancers of the gastro-intestinal
tract after abdominal radiotherapy, and of bone and soft tissue malignancies are all
increased after treatment with radiotherapy (Table .). However, since the absolute





































≤ 20 311 279 203 136 81 41 11
21-30 426 375 262 168 90 46 9
31-40 264 224 162 94 29 25 5
41-50 121 102  73 52 25 11 4
Figure 1.3: Absolute cumulative incidence of breast cancer in women treated with radiotherapy for HL.
Risk of breast cancer is highest in patients treated at a younger age. Data are collected from a cohort of 1122
Dutch HL survivors all treated with radiotherapy between 1965-1995 (27).
Table 1.3: Standardized incidence ratios of various types of secondary solid tumors
Type of cancer Standardized Incidence Ratio References
Breast cancer 1.3–11.6 (22, 28-32)
Lung cancer 1.8–6.7 (28–30, 32)
Thyroid cancer 3.1–8.6 (22, 28, 30, 31, 33)
Stomach cancer 1.6–9.5 (28, 30, 31, 33)
Oesofageal cancer 1.9–4.2 (28, 30, 31, 33)
Colon cancer 1.6–4.3 (28, 30, 31, 33)
Standardized incidence ratio reflects the proportion of observed secondary tumors in comparison to the number of expected tumors in
the general population.
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Cardiovascular disease
e most common nonmalignant long-term complication in HL survivors is devel-
opment of cardiac disease. Late cardiac complications are observed both in patients
treated with chemotherapy, and /or radiotherapy to the mediastinum. Since the ma-
jority ofHLpatients presentswith involvedmediastinal lymphnodes this area is often
included in the radiation treatment fields.
A wide spectrum of cardiovascular diseases may occur after mediastinal radio-
therapy. Historically, one of the most common radiation induced complications was
acute radiation pericarditis, due to increased vascular permeability leading to fluid
extravasation (). In - of patients this progresses into fibrotic thickening of
the pericardium, leading to chronic constrictive pericarditis ().e introduction of
linear accelerators has led to a decrease of the radiotherapy doses to the pericardium,
andwith the reduction of treatment fields, the incidence of pericarditis had decreased
significantly from  to , ().
In screening studies, valvular disease such as thickening, retraction and calcifica-
tion of the valves, is observed in up to - of patients treated with mediastinal
radiotherapy (, ). Valvular calcifications are most often seen at the aortic and
mitral valves. Valvular disease can lead to impaired functioning of the cardiac valves.
However, most patients remain asymptomatic up to the point where they present
with severe symptoms of heart failure ().
Conduction disorders have also been described after mediastinal radiotherapy,
due to either fibrosis of tissue adjacent to the conduction system or due to direct
damage (). Abnormalities most often concern right bundle branch blocks (), and
first-degree atrioventricular blocks (). Patients most commonly report episodes of
syncope.
Mediastinal radiotherapy fields often encompass the origin and proximal part
of the coronary arteries. Over time, this can lead to atherosclerotic coronary artery
disease. e pathogenesis of this process is likely to involve a variety of mechanisms.
Radiation damage to the vasculature of the heart can lead to an inflammatory re-
sponse (). is response leads to proliferation of the intima, the inner layer of the
vessel wall containing endothelial cells, and deposition of collagen. e subsequent
thickening of the endothelium can lead to dysfunction, which is believed to result
from a combination of impaired endothelial function, upregulation of growth fac-
tors and eventually fibrosis (). Progressive fibrosis and replacement of damaged
cells withmyofibrablasts along with platelet depositions then causes coronary plaque
formation and narrowing of the coronary artery vessel lumen resulting in coronary
artery stenosis ().
Coronary artery stenosis is a relatively frequent late complication in HL patients







whohave been treatedwithmediastinal radiotherapy. Severe coronary artery stenosis
can limit the blood flow to themyocardium and thus causemyocardial infarction, the
most common cause of cardiovascular death. e risk of myocardial infarction in HL
survivors has been evaluated in several epidemiological studies, and was compared
to an age- and sex matched normative population. Swerdlow et al. demonstrated a
hazard rate (HR) of . for mortality due to myocardial infarction in a cohort of 
HL survivors treated with mediastinal irradiation after a median follow-up of .
years (). In the Netherlands a comparable result was found by Aleman et al. among
 HL survivors (). e standardized incidence rate for myocardial infarction,
a measure that reflects the ratio of observed events as compared to the number of
events within a normal population, was .; which resulted in . extra patients with
myocardial infarction per . person years. Despite these established increased
risks of coronary artery disease and risk ofmyocardial infarction, the role of screening
for cardiac abnormalities remains unclear.
Other adverse physical late effects
Apart from second malignancies and cardiovascular disease, survivors from HL are
confronted with a variety of other adverse physical late treatment effects. Radiation
of the thyroid region can lead to impaired function of thyroid gland. Most often,
this involves a subclinical hypothyroidism, a decrease in thyroid function which is
compensated by elevated levels of yroid Stimulating Hormone. Impaired thyroid
function, if left untreated, can lead to a range of unexplained symptoms such as loss
of hair, dry skin, muscle aches but also feelings of loss of energy or depression. Sub-
clinical thyroid dysfunction is found in - of HL patients receiving radiotherapy
of the neck (-), and can be easily treatedwith oral thyroid hormone supplements.
Patients should be routinely screened for (subclinical) thyroid dysfunction. Radiation
of the shoulder and neck region in time can cause atrophy of muscles and fibrosis of
connective tissues. Symptoms range from stiffness and pain in the head and neck
region to the “dropped head syndrome” which is characterized by severe weakness
of the cervical muscles resulting in difficulties with keeping the head lifted and can
even cause complaints of severe headaches.ese symptoms aremost often seen after
treatment with mantle field irradiation, which encompasses a large proportion of
the neck- and shoulder musculature (). Prevalence increases over time, and ranges
between studies from  to  (, ). Some patients benefit from physiotherapy
treatment aimed at increasing muscle strength, or wearing a neck collar (, ).
With older treatment strategies, it was custom to remove the spleen for the pur-
pose of disease staging, or to irradiate the spleen to a high dose. Without (a func-
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tional) spleen the body is unable to respond adequately to certain types of bacterial
infections, which can result in the occurrence of rapid fatal infections. Preventative
strategies using pneumococcal and influenza vaccination schedules and prompt an-
tibiotics if needed should routinely be employed.
Fatigue and health-related quality of life
Apart from the risk of long-term adverse effects discussed above, many HL survivors
also report to suffer from long-termpsychosomatic and psychosocial problems. Since
the s there has been increasing interest in these aspects of late treatment se-
quelae, and in the burden associated with being a cancer survivor. Patient reported
outcome measures such as health-related quality of life studies are reported with in-
creasing frequency. ese studies have highlighted the specific needs and difficulties
of the growing population of cancer survivors (). HL patients are often treated and
cured at a young age, which means that late side effects of treatment influence a large
part of their adult life.
In daily practice, fatigue is one of themost frequently reported symptoms accom-
panying cancer, and often persists over time (). It often has a strong negative impact
on health-related quality of life, and is reported to be of more impact than pain or
other symptoms (). Several cross-sectional studies have evaluated the prevalence
of fatigue in HL patients. However, fatigue is also a frequently reported problem in
the general population. Only a few studies have compared prevalence of fatigue in
HL survivors to the general population, but all report a significant increase in fatigue
in HL survivors (, ). Also, the reported level of fatigue is significantly increased
compared to age- and sex matched control populations (, ).
Several studies have explored patient and treatment related factors influencing
levels of fatigue, but often provide conflicting results (, -). It therefore remains
difficult to indicate which factors have the largest impact on the occurrence and
persistence of fatigue. Better understanding of factors influencing fatigue could help
in developing specific interventions at prevention or treatment of adverse psycho-
somatic and psychosocial symptoms, or to improve information provision to cancer
survivors. It would also provide options for the training of clinicians in the care for
this specific population.







Outpatient late effects screening clinics (‘BETER’)
In view of the late side effects of treatment inHL, a nationwide network of specialized
long-termHL follow-up clinics has been started in theNetherlands, aimed at preven-
tion, early detection and treatment of late treatment sequelae and to ensure optimal
patient education and support. In the seven participating hospitals approximately
 HL survivors treated between - who should be considered for surveil-
lance at this dedicated outpatient clinic have been identified. A close collaboration of
radiation-oncologists, haematologists and epidemiologists will promote the develop-
ment of evidence-based follow-up guidelines and enhance possibilities for research
strategies for these patients. For HL survivors, the website www.beternahodgkin.nl
was developed, which offers detailed information on treatment and possible late
treatment sequelae.
1.3 Aims and outline of this thesis
e studies described in this thesis aimed to address and investigate several late ef-
fects of radiation therapy in HL survivors that have not yet been adequately studied.
InHL survivors, the risk of several secondary cancers such as breast cancer have been
well documented. However, little is known of the risk of secondary skin cancers due
to radiation treatment. In chapter  we report on the risk of developing skin cancers
after treatment for HL in a large patient cohort treated at Leiden University Medical
Center, and relate findings to an age- and sex matched norm population. Further-
more, epidemiological studies have established an increased risk of coronary artery
disease (CAD) inHL survivors, resulting in significantly increased risks ofmyocardial
infarction.e role of screening for CAD remains unclear. In chapter we report the
results of a phase II screening study among HL survivors who are considered to have
a high risk of radiation induced heart disease based on initial treatment parameters.
We also evaluated quality of information provision on late side effects and impact on
health-related quality of life of cardiac screening in this study population, which is
reported in chapter .
Health-related quality of life can be affected by late treatment sequelae. Among
the most frequently reported symptoms interfering with daily activities are fatigue
and loss of energy and vitality. Several studies have evaluated the prevalence of fa-
tigue and associations between patient and treatment related factors and severity of
fatigue. In chapter  we present an overview of current data on fatigue and factors
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influencing levels of fatigue. Many studies have focused on the association between
patient- and treatment characteristics and fatigue. Fatigue is also a frequent symptom
of depression. Little is known, however, of the relation between fatigue and depres-
sion or anxiety in HL survivors. Chapter  describes results from a cross-sectional
survey amongHL survivors assessing the association of fatigue with depression, anx-
iety and comorbidity, and comparison of the results with those from an age- and sex
matched normative population.
In Chapter  the main findings of the studies in this thesis are summarized and
discussed, and the implications of these and other studies for long-term follow-up
and screening of HL survivors are put into clinical perspective. Specific recommen-
dations for future studies and for long-time care, counseling and support of HL sur-
vivors are made, with the aim of improving their event-free survival and quality of
life.
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chapter 2
Long-term risk of secondary skin cancers after
radiation therapy for Hodgkin lymphoma











Survivors of Hodgkin’s lymphoma (HL) are at risk of secondary tumors. We inves-
tigated the risk of secondary skin cancers after radiotherapy compared to treatment
without radiation and to an age-matched population.
Methods
We conducted a retrospective cohort study of  HL patients treated between 
and . Data on secondary skin cancers and treatment fields were retrieved. Inci-
dence rates were compared to observed rates in the Dutch population.
Results
 skin cancers were diagnosed in  patients, showing significantly higher risks
of skin cancers, the majority being BCC. e standardized incidence ratio (SIR) of
BCC in HL survivors was significantly increased (SIR .,  CI .–.), especially
in those aged < years at diagnosis (SIR .,  CI .–.). SIR increased with
longer follow-up to . ( CI .–.) after  years, with  excess cases per
. patients per year. Most () skin cancers developed within the radiation
fields, with significantly increased risk in patients treated with radiotherapy com-
pared to chemotherapy alone (p=., HR .,  CI .–.).
Conclusions
Radiotherapy for HL is associated with a strongly increased long-term risk of sec-










With the introduction of effective chemotherapy agents and the development of
modern radiotherapy techniques, the overall and relapse-free survival rates for pa-
tients with Hodgkin’s lymphoma (HL) have improved dramatically. With increasing
numbers of long-term survivors of HL, the evaluation of late treatment sequelae has
become of major importance.e increased long-term risk of secondary cancers due
to radiotherapy has been established in numerous studies (-). e excess risks of
several types of secondary tumors in or near the previous radiation fields have been
found to be associated with radiation dose, time since radiation and age at initial
treatment (, ). Patients treated at a young age, those treated to the mediastinal and
axillary lymph nodes with relatively high doses of radiotherapy, and especially those
treated with extended (subtotal nodal) radiation fields are at risk for developing sec-
ondary cancers (). Increased rates of secondary solid tumors, such as breast cancer,
are usually seen from  to  years after exposure to irradiation onward (-).
Epidemiological studies have established previous radiation therapy as a risk fac-
tor for the development of skin cancers,mainly basal cell carcinoma (BCC)().ese
studies have predominantly described large cohorts of children, treated at a very early
age with moderate radiation doses. Shore et al. reported a relative risk of . for the
development of skin cancer when comparing a cohort of . children irradiated
with a median dose of . Gy to the scalp for tinea capitis to a control group of .
children merely treated with topical medications ().
Several case-control studies have found similar odds ratios (OR)(). Watt et al.
compared  childhood survivors of cancer developing BCC during follow-up to
 age-matched childhood survivors without BCC and found an increased risk for
BCC in patients treated with radiotherapy. Risk of developing BCC increased with
higher radiation treatment dose().
Few studies inHL survivors have focused on the risk of developing secondary skin
cancers: Swerdlow et al. reported a significantly increased standardized incidence
ratio (SIR) of non-melanoma skin cancer of . in  patients treated for HL().
Increased risks ofmelanoma (SIR .) have been described inAustralianHL survivors
().
e present study was undertaken to investigate the long-term risk of developing
secondary skin cancer after radiation therapy (RT) in a large cohort of HL survivors
compared to those treated without RT and to the general Dutch population, and to
relate the location of skin cancers to the radiation fields.
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Methods
Patients and treatment
Leiden University Medical Center (LUMC) is a regional center of expertise for di-
agnosis and treatment of HL patients. Data on all treated oncology patients are col-
lected in a central database. We conducted a retrospective cohort study of all HL
patients treated between  and  to establish the incidence of skin cancers in
HL patients treated with radiation therapy alone or with combined modality treat-
ment (radiotherapy and chemotherapy, either as primary treatment or at relapse) in
comparison to those treatedwith chemotherapy alone.e timeframe -was
chosen to assess long-term risks and have a sufficient time interval since treatment
to analyze radiation-induced tumors, which usually develop from  to years after
treatment onwards.
From the LUMC cancer registry system (OncDoc) we collected information on
age at diagnosis, gender, stage of HL, treatment modality, treatment phase (primary
treatment or for recurrent disease), survival and date of death. OncDoc performs an
independent and active follow-up by annually updating their database through the
DutchMunicipal PopulationRegistries, supplementedwith data from the nationwide
network and registry of histo- and cytopathology in the Netherlands (PALGA()),
patient files and contact with family doctors in case of patients lost to follow-up or
with unknown cause of death. is resulted in this study in a nearly complete ()
follow-up registration up to January th .
For information on the occurrence of skin cancers in HL patients we consulted
PALGA().is is a nationwide organizationwith a central archive for pathology re-
ports from all pathology laboratories in the Netherlands, which was founded in ,
and had increasing participation in subsequent years. Since  the registration has
nationwide coverage. After the PALGA Internal Review Board approval, a search of
subsequent pathology diagnoses in our HL patient cohort was conducted to identify
those diagnosed with skin cancers. e search was performed by matching patients
on date of birth, sex, and last name.
Skin cancer was defined as a histological diagnosis of basal cell carcinoma (BCC),
squamous cell carcinoma (SCC) or melanoma of the skin. Date(s) of diagnosis and
site(s) of first and any subsequent occurrence of skin cancer were established from
the PALGA reports. Data were extracted on January th . For patients who
had developed skin cancers, detailed information on HL treatment and location and
dose of the radiation treatment fields was collected in order to examine the type and
location of the secondary skin cancers in relation to the radiation fields and doses.








Incidence rates of skin cancers, including BCC which was the predominant form
of skin cancer in our cohort, were compared to observed incidence rates in the
Netherlands obtained from the population-based Cancer Registry of the Compre-
hensive Cancer Center South (for BCC) and the Netherlands Cancer Registry (for
SCC and melanoma)(, ).
Statistical analysis
All statistical analyses were performed using SPSS statistical software for windows
version  (SPSS inc., Chicago, IL, USA) and STATA statistical software for windows
version  (StataCorp LP, College Station, Texas, USA). Differences in characteristics
of patients treated with chemotherapy alone or with radiotherapy were evaluated
using chi-square (categorical variables) and analysis of variance (numerical variables).
Correlations of skin cancer locations to the radiation fields were done in a descriptive
manner.
e number of first skin cancers (BCC, SCC or melanoma) in the cohort was
compared with the expected number in the Dutch population, based on age, sex-
and calendar period- specific incidence rates for the period from  through .
Time at risk started at date ofHLdiagnosis. Because the registration of the occurrence
of skin cancers by PALGA was not complete until , we left-censored within the
timeframe –. erefore, patients at risk between  and  did not
contribute person-time to our analysis during this timeframe. Time at risk ended
at an event of a first skin cancer occurrence, last date of follow-up, death or other
loss to follow-up, whichever occurred first. e SIR, defined as the observed (O)
divided by the expected (E) numbers of BCC, SCC and melanoma were determined
and corresponding  confidence intervals were calculated based on the Poisson
distribution of observed numbers. Absolute excess risks (AER) were calculated as
the observed incidence of skin cancers minus the number expected, divided by the
number of person-years at risk and multiplied by ,.
Cumulative incidence of skin cancer in HL survivors treated with and without
radiotherapy was estimated accounting for death as competing risk (). To deter-
mine the influence of the possible incomplete event registration between  and
, results were calculated both without and with left censoring. Hazard ratios
and  confidence intervals (CI) were calculated by competing risk regression, both
unadjusted and corrected for age, sex, year of diagnosis, and treatment period. A two-
sided p-value <. was considered statistically significant.
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Table 2.1: Characteristics of HL survivors cohort
Total number
of patients
% RT % No RT % P-value
Total 889 750 139




Chemo- and radiotherapy 499 56
Sex p=0.13
Male 505 57 418 56 87 62
Female 384 43 332 44 52 38
Year of diagnosis p=0.60
1965-1975 216 24 171 23 45 33
1976-1985 233 26 194 26 39 28
1986-1995 231 26 200 26 31 22
1996-2005 209 24 185 25 24 17
Stage (Ann-Arbor) p<0.001
I 209 23 204 27 5 4
II 456 51 437 58 19 14
III 103 12 44 6 59 42
IV 104 12 51 7 53 38
Unknown 17 2 14 2 3 2
Relapse p=0.86
Yes 187 21 157 20 30 22
No 702 79 593 80 109 78
* including treatment for relapse. RT = radiotherapy.
Results
Between January st  andDecember st  a total of  patients were treated
for HL at LUMC. Median age at diagnosis was  years (range - years). Of these,
 patients () were treated with chemotherapy alone,  () with radiother-
apy alone and  ()with a combination of these twomodalities, either as primary
treatment or as treatment for relapse of disease. Table . gives an overview of patient







Table 2.2: Characteristics of patients with skin cancer
Treatment Number %
Radiotherapy 39 45
Chemotherapy and radiotherapy 43 50
Chemotherapy only 4 5
Mean dose of radiotherapy (Gy, range) 35 (24-45)






Age and time interval Years Range
Median interval of HL treatment to skin cancer 18 1-37
Median age at diagnosis of first skin cancer 52 25-80
Number of skin cancers Number %
Total number of skin cancers 318
Mean number of skin cancers per patient (range) 4 (1-44)
1 44 52
2 -5 28 33
6-10 8 8
≥11 6 7
Histology of skin cancers Number %
Total 318 100
Basal cell carcinoma 294 93
Squamous cell carcinoma 14 4
Melanoma of the skin 10 3
Relation of skin cancer to radiation field (per skin cancer) Number %
No radiotherapy 10
Radiotherapy 308
Within radiation field 175 57
Outside radiation field 87 28




Relation of skin cancer to radiation field (per patient) Number %
No radiotherapy 4
Radiotherapy 82 100
Within radiation field 23 28
Outside radiation field 23 28




* Subgroup of skin cancers developing outside radiation fields.
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Table 2.3: Standardized incidence ratios of first skin cancer in HL survivors
Diagnosis Observed Expected SIR 95 % CI AER*
Skin, melanoma 6 2.3 2.6 0.9-5.6 3.6
Skin, squamous cell 10 1.9 5.0 2.4-9.2 7.9
BCC of skin, head & neck 17 8.0 2.1 1.2-3.4 8.8
BCC of skin, trunk 36 3.0 11.7 8.2-16.2 32.4
BCC of skin, limbs 3 1.7 1.7 0.3-5.0 1.2
BCC of skin, other & NOS 11 .05 185.6 92.7-332.1 10.8
BCC of skin, total 67 12.9 5.2 4.0-6.6 53.3
Abbreviations: BCC = basal cell carcinoma; SIR = standardized incidence ratio; CI = confidence interval; AER = absolute excess risk;
NOS = not otherwise specified.
* per 10.000 persons per year.
Over the time period considered,  patients developed a total number of 
skin cancers at a median interval of  years (range - years). Mean number of
subsequent skin cancers was  per patient (range -). Among the  skin cancers,
 ()were BCC,  ()were SCCand  ()melanomas of the skin (Table .).
When comparing the incidence rates of BCC, SCC and melanoma in our patient
cohort to the incidence rates found in the Dutch population, the overall SIR for de-
velopment of BCC was . ( CI .-., Table .), resulting in  excess cases of
BCC per , persons per year. SIRs for SCC and melanoma were . ( CI .-
.) and . (CI .-.), respectively.When comparing incidence rates of BCC at
specific anatomic locations, the rates were especially increased in the chest and trunk
area (SIR .,  CI .-.), which is the predominant location of radiotherapy
fields since most patients received either mantle fields or mediastinal involved field
radiotherapy.
e SIR for BCC was clearly higher in patients who had received radiotherapy as
part of their treatment, than in those who received chemotherapy alone (Table .).
SIRs after radiotherapy were . ( CI .-.) for radiotherapy alone and .
( CI .-.) for combined modality treatment (CMT), compared to . ( CI
.-.) after chemotherapy (CT) alone.
e risks of developing secondary BCC were especially increased in patients
treated for HL before the age of  years (SIR .  CI .-., Table .) and
those treated between  and  years of age (SIR .,  CI .-.) and close to
unity in patients treated after the age of . SIRs increased with longer follow-up;
after  years the SIR was . ( CI .-.), with  excess cases per .








Table 2.4: Risk of first BCC compared to the general Dutch population
Sex PY O SIR 95% CI AER*
Male 5415 39 5.7 4.0-7.7 59.4
Female 4740 28 4.6 3.0-6.7 46.2
Age at diagnosis PY O SIR 95% CI AER*
<35 7341 46 8.0 5.8-10.7 54.9
35-65 2653 20 3.1 1.9-4.9 51.7
>65 161 1 1.1 0-6.2 6.8
Treatment PY O SIR 95% CI AER*
CT 3073 4 2.6 0.7-6.6 22.5
RT 1086 33 7.9 5.5-11.2 93.9
RT + CT 5996 30 4.1 2.8-6.0 38.0
Treatment period PY O SIR 95% CI AER*
1965–1975 1747 25 7.1 4.5-10.5 122.9
1976–1985 2749 13 3.5 1.9-6.1 33.9
1986–1995 3726 20 5.1 3.2-7.9 43.3
1996–2005 1932 9 4.8 2.2-9.1 36.9
Follow-up interval PY O SIR 95% CI AER*
0–1 yrs 395 0 0 - -
1–5 yrs 1676 2 1.8 0.2-6.3 5.1
5–10 yrs 2082 5 3.0 0.9-7.0 16.0
10–15 yrs 1829 4 2.1 0.6-5.5 11.7
15–20 yrs 1572 6 2.8 1.0-6.2 24.7
20–25 yrs 1215 14 6.7 3.7-11.3 98.1
25–29 yrs 745 10 6.3 3.0-11.7 113.0
30–34 yrs 400 10 8.0 3.8-14.7 218.7
>35 yrs 239 16 15.9 9.1-25.9 626.4
Abbreviations: PY = person years; O = observed; SIR = standardized incidence ratio; CI = confidence interval; AER = absolute excess
risk.
* per 10.000 persons per year.
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Figure 2.1: Cumulative incidence of developing a first skin cancer in the HL survivor cohort after treatment
which included radiotherapy (RT; either RT alone or combined modality treatment) vs. treatment with
chemotherapy alone (No RT).
e risk of development of skin cancer was significantly increased in patients
who had received RT as (part of ) their treatment, when compared to those treated
with chemotherapy alone (unadjusted p=·, HR .,  CI .-., adjusted
p=.,HR., CI .-.). Cumulative incidences of developing skin cancer
were .,  and  at ,  and  years after treatment with radiotherapy,
respectively, compared to ., . and , respectively, for those treated with
chemotherapy alone (see Figure .).
e correlation of each separate skin cancer to the radiation fields is described in
Table .. e majority of skin cancers developed within radiation fields (). For
those developing outside treatment fields an assessment was made of the distance to
the radiation field borders, given that skin cancers in close proximity to the radiation
treatment fields could have developed either due to scatter irradiation near the field,
or within the radiation penumbra. Of the  skin cancers that had developed out








skin tumors no relation to the radiation fields could be established, due to missing
descriptions of precise anatomic locations in PALGA pathology reports.
Of the  skin cancers developing within five years after initial treatment for HL,
 developed within the radiation treatment fields (). In contrast, of the  skin
cancers developing more than  years after treatment,  () developed within
the radiation field.
Among patients who developed secondary skin cancers,  developed tumors
only within radiation fields,  developed skin cancers both within and out of the
fields, and  only outside the radiation fields ( unknown, Table .). ese
numbers changed only slightly when limiting the analysis to BCC ( within fields,
 both within and out of field). Among the patients with only one BCC,  of the
tumors developed within field.
Most skin cancers were treated with simple excision, but specific information on
subsequent follow up was not available. None of the patients died from the results of
basal cell carcinoma, squamous cell carcinoma or melanoma of the skin.
Discussion
is study investigated the long-term risk of developing secondary skin cancers in a
large cohort of HL survivors. We found significantly increased risks of subsequent
skin cancers in HL patients treated with radiation therapy as compared to those
treated with chemotherapy alone. e predominant form of skin cancer observed
was BCC. Risks of developing BCC were substantially increased when compared to
the general Dutch population and strongly increased with longer follow-up.
To our knowledge, this is one of the largest cohort studies presenting risks of
skin cancer in patients treated with moderately to high doses of radiotherapy, with
long-term and nearly complete follow-up. We calculated cumulative incidence rates
of developing skin cancer with death as competing risk and found incidences of .,
 and  at ,  and  years after treatment with radiotherapy, compared to
., . and  for those treatedwith chemotherapy alone. Furthermore, we found
a SIR of . for BCC, resulting in  excess cases of BCC per . persons per
year in our HL cohort, when compared to the general population in the Netherlands.
As BCC are not registered in the Netherlands Cancer Registry we compared our
data to population data from Cancer Registry of the Comprehensive Cancer Center
South (CCCS), which is the only registry of BCC incidence in the Netherlands. e
increased rates found in our study are comparable those found by Swerdlow et al.
30 | Long-term risk of secondary skin cancers after radiation therapy for Hodgkin lymphoma
(). When assessing location-specific rates we found increased rates in the chest
and trunk area. is observation can be explained by the fact that most patients
received radiotherapy to that area either as part of a mantle field or involved field
irradiation. e high rates of BCC found in the not otherwise specified (NOS) group
are due to the fact that our cohort had more missing anatomic locations than the
CCCS registry. With respect to the effect of treatment, data showed the highest rates
of BCC in those treated with radiotherapy alone. e lower, but still significantly
increased, rates found in the combined modality group, could be due to the fact that
these patients were more often treated with smaller, radiotherapy fields.
Several mechanisms for development of radiation-induced malignant neoplasms
have been postulated (). Ionizing radiation can result in sublethal DNA damage
which could cause genetic changes. ese changes may contribute to malignant
transformation in the irradiated tissues, even after low doses of irradiation. is
might explain the increased incidence of skin cancers in patients who received RT
as (part of ) their treatment. e observed interval of  years and more for increased
risks of developing skin cancers was also found in other studies reporting on sec-
ondary malignancies after cancer treatment. Since the majority of our HL cohort has
not yet reached a follow-up duration over  years, and absolute risks of developing
skin cancer increase with older age, the total number of skin cancers is expected
to further increase in the upcoming years, implicating a substantial and clinically
relevant problem.
Due to the retrospective nature of our study, certain potential confounding fac-
tors could not be evaluated. Smoking habits, (work-related) sun exposure, age, light
skin type or family history are established risk factors for developing BCC (-),
which were by far the most frequent skin cancers in our cohort. One patient in our
cohort developed a total of  subsequent skin cancers in a time period of  years.
An influence of genetic predisposition for developing skin cancer can therefore not
be ruled out. Since medical records of patients in our cohort were often incomplete
for skin cancer risk factors other than radiation, our data could not be analyzed with
adjustment for these risk factors. It is unlikely, however, that these factors would dif-
fer considerably between patients receiving radiotherapy and those who were treated
with chemotherapy alone. Given themedian time interval of  years to development
of the first skin cancer after primary treatment, a retrospective study is probably the
only feasible type of research for this purpose.
To ensure an independent and complete report on the development of skin can-
cers in our cohort we used the PALGA database for histological confirmation. In
principle it could be that some skin cancers, mainly BCC, were treated without his-
tological confirmation. erefore it is possible that the observed incidence rates in








Radiotherapy has played an important role in HL treatment since the s. Ex-
tended field radiotherapy has long been (part of ) standard treatment. Such extended
fields exposed large parts of the patient’s body to radiation. Current combined treat-
ment approaches for early stage HL with - cycles of chemotherapy followed by
lower doses of involved field radiotherapy, and more recently involved node radio-
therapy, have resulted in significantly reduced irradiated volumes (, ). Complete
omission of radiotherapy in early stage HL has been shown to lead to increased local
relapse rates (, ). With radiotherapy as an important element in the treatment of
HL, patients will continue to be at risk for late adverse events due to their treatment.
Patient and doctor awareness of the increased risk of developing skin cancers in
addition to the established risk of secondary solid tumors such as breast cancer, lung
cancer or gastrointestinal cancers is therefore essential (-). Increased awareness
will lead to reduced morbidity by means of preventive measures (such as reduction
of sun exposure) and early detection (-). In this light, a nationwide network of
specialized long-term HL follow-up clinics has been started in the Netherlands, to
ensure optimal patient education, aimed at prevention and early detection of late
treatment sequelae ().
In conclusion, our cohort study shows a substantially increased risk of secondary
skin cancers in HL survivors receiving radiotherapy as part of their treatment, both
compared to the general Dutch population and to those treated with chemotherapy
alone.is excess risk remains increased for at least  years after treatment. Patients
and health care providers should be aware of this risk, in order to facilitate preventive
measures and rapid access to early diagnosis and treatment.
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chapter 3
Screening for coronary artery disease after
mediastinal irradiation in Hodgkin lymphoma
survivors: phase II study of indication and
acceptance












Cardiovascular diseases are the most common nonmalignant cause of death in
Hodgkin lymphoma (HL) survivors, especially after mediastinal irradiation. We in-
vestigated the role of computed tomographic coronary angiography (CTA) as a
screening tool for coronary artery disease (CAD) in asymptomatic HL survivors, and
related CTA findings to exercise testing and subsequent interventions.
Patients and methods
Patients were eligible for this phase II study if at least  years disease-free and treated
with mediastinal radiotherapy. Screening consisted of electrocardiogram, exercise
testing and CTA. Primary endpoint was significant CAD (stenosis >) on CTA.
CTA screening was considered to be indicated for testing in a larger population if ≥
 out of  CTA scanned patients () would need revascularization. Screening was
evaluated with a questionnaire before and after screening.
Results
Fifty-two patients were included, and  patients underwent CTA. Median age was
 years, time since HL diagnosis  years. ere were  evaluable scans. Signifi-
cant CAD on CTA was found in  (N=), significantly increased compared with
the  expected abnormalities (p=.,  CI .-.). In  (N=) significant
stenosis was confirmed at coronary angiography, and revascularization was carried
out. Additionally, two patients were treated with optimal medical therapy. Ninety
percent of patients were content with screening, regardless whether the CTA showed
abnormalities.
Conclusions
Prevalence of significant CAD among HL survivors is high, while asymptomatic
even in the presence of life-threatening CAD. is might justify screening by CTA
in asymptomatic HL survivors who had mediastinal radiotherapy, but needs to be









Over the past  years, disease-specific survival in Hodgkin lymphoma (HL) patients
has increased dramatically due to improved treatment strategies. However, HL sur-
vivors remain at risk of developing late treatment sequelae resulting in increased
morbidity and mortality. Cardiovascular diseases (CVD) are the most common non-
malignant cause of death in these patients (). A three- to fourfold increased risk
of myocardial infarction due to coronary artery disease (CAD) has been observed,
especially in HL survivors who had mediastinal irradiation as monotherapy or in
combination with chemotherapy (, ). e course of CAD in HL survivors is often
asymptomatic, even in the presence of severe stenosis (). Traditional risk assessment
therefore fails to identify HL survivors at high risk for myocardial infarction. More
rigorous surveillance in this population seems warranted. e current gold standard
for detecting CAD, invasive coronary angiography (CAG), is unsuitable for screening
purposes due to risks of complications and mortality. A recent review of studies
investigating noninvasive screening techniques for CAD in HL survivors reported
disappointing test characteristics of exercise testing, with a reported sensitivity for
significant CAD stenosis of only . Moreover,  subsequently developed symp-
tomatic CAD within a follow-up duration of . years (). Recently, high diagnostic
accuracy of screening with computed tomographic coronary angiography (CTA) has
been shown in symptomatic patients at intermediate or high risk for CAD (). A
recent study using CTA as a screening tool for CAD among childhood survivors of
HL showed a high prevalence of coronary abnormalities ().
epurpose of this phase II studywas to investigate the role of CTAas a screening
tool for CAD in asymptomatic HL survivors who underwent mediastinal irradia-
tion as part of their treatment, to relate CTA findings to electrocardiogram (ECG)
exercise testing, and to determine the frequency and type of subsequent coronary
interventions prompted by CTA. In addition, health-related quality of life (HRQL)
and acceptance of screening among patients included in the study was evaluated,
both before and after cardiac screening.
Methods
Patients
Long-term HL survivors treated at the departments of Radiation Oncology and
Hematology at Leiden University Medical Center (LUMC) were invited to partici-
38 | Screening for coronary artery disease after mediastinal irradiation in HL survivors
pate. Patients with all stages of HL who were at least  years disease-free and had
received mediastinal radiotherapy as part of their treatment were eligible. Exclusion
criteria were age> years; current treatment of CVD other than hypertension, dys-
lipidemia or minor valve defects; previous CTA in the past  years; renal function
impairment; known contrast allergy and/or presence of a life-threatening disorder.
Study protocol
is was a single-institution phase II study. e trial protocol was approved by
the LUMC Ethics Committee and registered with ClinicalTrials.gov, NCT.
After obtaining written informed consent, information on patient and treatment
characteristics including radiation treatment fields and dose, and type and dose
of (anthracycline-containing) chemotherapy were collected from patient files. Pa-
tients were referred to the Cardiology Outpatient Clinic for extensive cardiovascular
screening. is included a detailed patient history focusing on specific symptoms
and risk factors for CVD, physical examination, fractionated serum cholesterol and
glucose testing, resting ECG, echocardiography and symptom-limited exercise ECG
testing (). At a separate visit, cardiac CTA imaging was carried out using a -
detector row volumetric scanner (AquilionONE,ToshibaMedical Systems,Otawara,
Japan) according to standard clinical practice (). Patients with a heart rate above 
beats/min received  or  mg metoprolol orally  h before imaging, unless con-
traindicated. In addition, sublingual nitroglycerin (. or . mg sublingual) was ad-
ministered min before the start of the scan ().Noncontrast-enhanced and contrast-
enhanced scans were carried out. e nonenhanced scans were used to assess the to-
tal amount of coronary artery calcium score according toAgatston (). CTAdatasets
were evaluated for plaque constitution in a consensus reading by two experienced ob-
servers, whowere aware of the patients history regarding radiation treatment, but not
of any possible current symptoms. Results of CTA were classified as normal (<
luminal narrowing), nonsignificant CAD (- luminal narrowing) or significant
CAD (> luminal narrowing).
Results of all examinations and potential indications for further analysis or treat-
ment were discussed during a subsequent visit. If a significant coronary stenosis was
observed on CTA, diagnostic coronary angiography was carried out, according to









Patients were asked to complete three validatedHRQLquestionnaires at baseline and
at completion of the study. e EORTC QLQ C- questionnaire measures health-
related quality of life (). e EORTC INFO- measures patient satisfaction with
regard to received information on treatment (); and the FAS (fatigue assessment
scale) is a rating scale for fatigue and loss of energy (). An additional short ques-
tionnaire of nine items, designed specifically to evaluate acceptance of screening, was
added (see appendix Chapter ).
Study design
Primary endpoint was the presence of significant CAD (>  stenosis) on CTA.
With an estimated rate of  significant coronary disease in asymptomatic healthy
individuals (), and increased relative risk of three in HL survivors (), we expected
to identify significant coronary stenoses in - of our HL population. A sample
size of  patientswould achieve≥power to detect a threefold relative increase of
 to , and thus an absolute increased risk of , using a two-sided binominal
test with α ≤.. With an expected prevalence of significant coronary stenoses of
, it is assumed that  out of  scans will demonstrate significant CAD. Allowing
for false-positive scans, we considered CTA screening to be indicated for testing in
a larger population if in ≥  patients out of  CTA scanned patients () revascu-
larization would be indicated.
Secondary objectives were to determine the frequency and type of subsequent
interventions, to compare CTA findings to exercise ECG testing results, to evaluate
HRQL and acceptance of screening, and to compare prevalence and location of coro-
nary artery stenoses to CTAfindings from an age, sex and risk factormatched control
population.
40 | Screening for coronary artery disease after mediastinal irradiation in HL survivors
56 patients eligible 
4 patients refused 
52 patients included 
3 patients withdrew consent 
1 diagnosed with new lung nodus, 1 pregnant, 
1 did not want screening 
49 started screening protocol 
1 patient without CTA 
diagnosed w severe aortastenosis, immediate CAG  
and valve replacement. No significant CAD. 
48 finished screening protocol 
45 patients with evaluable CTA 
3 patients CTA poor quality,  
no evaluation possible 
Figure 3.1: CONSORT diagram for CTA analysis
Statistical analysis
All statistical analyses were performed using SPSS statistical software for windows
version . For the analysis of the primary endpoint all patients with evaluable CTAs
were included. Analyses of secondary objectives were done in a descriptive manner.
Evaluation of HRQL was done by using EORTC guidelines (). Prevalence, location
and aspect of CAD in our study population were compared to sex, cardiac risk fac-
tor and age-matched cases from an ongoing CTA registry at the LUMC Cardiology
Department containing CTA results from> patients presenting with chest pain









Patients were included between January  and March  (Figure .).
Among the  included patients,  withdrew after signing informed consent. One
patient did not undergo CTA due to immediate intervention for severe aortic valve
stenosis. e remaining  patients completed the screening protocol. Character-
istics of the  patients finishing the CTA screening protocol are summarized in
Table .. Median age was  years (range - years),  was female. irteen
patients () had been treated with radiotherapy as monotherapy,  with com-
binedmodality treatment.Median dose ofmediastinal radiotherapywas Gy (range
- Gy). Radiotherapy volumes most frequently used were involved field in 
patients, mantle fields (mediastinal and axillary fields) in  and subtotal nodal fields
(mediastinal, axillary, para-aortic and splenic fields) in .
Nine patients received a cumulative anthracycline dose of ≥ mg/m (median
dose  mg/m). Most patients had no risk factors for developing CAD; the risk
factor most frequently reported was BodyMass Index (BMI)>, which was present
in  patients (median BMI  kg/m). Detailed treatment characteristics of patients
with abnormal CTA results are described Table ..
CTA results
In total,  patients underwent CTA. Due to increased heart rates resistant to β-
blocking agents and resulting in motion artefacts on CTA, three scans were not
evaluable. Another  scans were of suboptimal quality, due to the same problem, but
were of sufficient quality for evaluation. In the  scans available for assessment, the
prevalence rate of significantCADonCTAwas  (N=, p=., CI . - .)
and thus significantly increased compared with the expected population prevalence
rate of . Eight of nine patients with significant CAD on CTA were classified as
having a low risk for developing CAD, according to the Framingham Risk Score
(). Eight patients with significant CAD on CTA underwent CAG. In five of these
patients significant proximal CAD was confirmed and revascularization procedures
carried out, amongwhich two coronary artery bypass grafts for severe leftmain artery
stenosis. e remaining three patients did not need revascularization, but two were
started on drug therapy with statins and platelet inhibition (Table .). Accuracy of
CTA, defined as the confirmation of abnormalities on CAG resulting in a subsequent
intervention was  (seven out eight patients who underwent CAG). One patient
with possibly significant CAD on CTA refused subsequent CAG, since she had been
Table 3.1: Patient and treatment characteristics
Number of patients %
Total 48
Sex Number of patients %
Male 19 40
Female 29 60
Age and time interval Years Range
Median age at diagnosis HL 26 (15-37)
Median age at time of study 47 29-60
Median time since diagnosis 21 11-29





Treatment Number of patients %
Median dose mediastinal radiotherapy (range) 36 (24-40)
Number of patients receiving combined modality treatment 35 73
Number of patients >300 mg/mm2 anthracycline 9 19






Cardiovascular risk factors Number of patients %
Cigarette smoking 4 8
Hypertension 4 8
Diabetes mellitus 0 0
Dyslipidaemia 6 13
Family history positive for myocardial infarction 8 16
Body mass index >25 19 40
MOPP = mechlorethamine, vincristine, procarbazine, prednisone; MOPP-ABV = mechlorethamine, vincristine, procarbazine,
prednisone/doxorubicin, bleomycin, vincristine; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; EBVP = epirubicin, bleomycin,
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diagnosed with breast cancer at the time of CTA. Patients with significant CAD on
CTA more often had high calcium scores (th–th percentile) than patients who
had no severe abnormalities on the CTA scan ( compared to , Table .).
Matched case-controls
For the nine patients in our study with significant CAD on CTA, the LUMC Cardiol-
ogy database was searched for matched cases. Due to young age and absence of risk
factors in the HL survivors, only a single matching case could be found.
Among the HL patients with CAD on CTA  (seven of nine) were treated,
either with optimal medical treatment or intervention, while in the matched cases
eventually only  (two of nine) had significant CAD on CTA necessitating treat-
ment. ese small numbers impaired comparison of location or aspect of coronary
stenosis.
Exercise ECG testing versus CTA
Results fromECGexercise testingwere related to findings onCTA (Figure .).Of the
 patients that started the screening protocol,  were not able to perform an exercise
test due to physical impairments. ese three patients had no signs of significant
CAD on CTA. e remaining  patients underwent both ECG exercise testing and
CTA. None of the patients had complaints of angina pectoris during the test. ree
patients had signs of ischemia on ECG during exercise testing. Presence of significant
CAD was found in only one of them. Of the  patients with a normal exercise test,
 had significant CAD on CTA and CAG was carried out in . Revascularization was
needed in four, and two were started on drug therapy. e two patients with severe
left main artery stenosis on CTA and CAG showed no signs of ischemia during the
ECG exercise test.
HRQL and acceptance of screening
Forty-seven patients () participated in theHRQLpart of this study and completed
the first set of questionnaires;  completed the second questionnaires, resulting in a
response rate of .All patientswhounderwentCAGreturned both questionnaires.
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exercise testing 
total no patients 
 N=48 
exercise test negative 
 N=42 
no exercise test 
 N=3 















CTA not evaluable 
N=3 
CAG 
CAG + revascularisation 
N=1 
CAG + medical intervention 
N=2 
CAG + revascularisation     
N=4  
CAG, no intervention N=1 
No CAG N=1  
Figure 3.2: Results of exercise ECG testing versus CTA
they were content with participating in the screening study. Visiting the cardiac out-
patient clinic and undergoing the CTA was perceived cumbersome by  and 
respectively.
e emphasis that was placed on the possible cardiac effects of treatment of HL
was perceived as bothersome by . Full analysis of HRQL will be described in a
separate publication.
Discussion
is phase II study investigated the role of CTA as a screening modality for CAD in
asymptomatic HL survivors. We detected a  prevalence rate of significant ostial
or proximal coronary artery stenosis on CTA, the majority of which was confirmed
with CAG. Another  (N=) of the study population had an abnormal CTA, with








Prevalence of CAD on CTA was high, especially considering the fact that almost
all patients were categorized as having a low risk for developingCAD, based on young
age and absence of risk factors such as smoking or dyslipidemia. Comparing the HL
patients to matched cases proved to be difficult, which underlines the fact that HL
survivors do not fit the usual high-risk cardiac profile. Only a small proportion of the
HL survivors had received a cardiotoxic cumulative dose of chemotherapy, suggest-
ing that previous radiation treatment may be the most probable cause of CAD. e
prevalence of coronary stenosis found in this study is likely to be an underestima-
tion of the true occurrence of CVD, since patients with already apparent CAD were
ineligible.
In our study,  of the  evaluable patients (), close to the predefined ,
underwent revascularization procedures. Another two were treated with optimal
medical therapy, resulting in a prevalence rate of patients with severe abnormalities
needing interventions of  ( of ). One patient did not complete screening due
to immediate treatment of severe aortic valve stenosis.
e potential role of CTA as a screening tool for CAD in asymptomatic HL sur-
vivors was tested in two other studies. In a small pilot study including nine patients
with a treatment history of mediastinal radiotherapy and a median follow-up dura-
tion of  years, Rademaker et al. found five patients with stenoses>, of whom 
were subjected to CAG and required revascularization. However, in this study most
patients had additional risk factors for developing CAD (). Kupeli screened 
childhoodHL survivors ofwhomhad receivedmediastinal radiotherapy (median
dose . Gy) after a relatively short median follow-up period of  years. Abnormal-
ities on CTA were found in , but only one patient underwent subsequent CAG
(). Although the number of patients in our pilot study is limited, one of the strengths
is that in almost all patients with significant stenosis on CTA CAG was carried out
to confirm CTA results.
Our study compared different types of noninvasive screening. Only one patient
with significant CAD was accurately identified by ECG exercise testing, and none
of the participating patients reported symptoms, not even in the presence of severe
CAD. ese observations confirm the limited value of screening by means of ECG
exercise testing in this setting as reported in the literature ().
Considering these results, and with the knowledge that it has been demonstrated
that the predictive value of a negative CTA is high for excluding CAD and correlates
with a low risk of cardiac death in the near future (), it seems justified to conclude
that CTA is an effective, and possibly themost suitable noninvasive screeningmodal-
ity for CAD in asymptomatic HL survivors.
CTA screening and cardiac intervention in this population might be advisable,
provided that treatment that improves outcome for those with screen-detected ab-
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normalities is available. Survival benefit of cardiac interventions has been demon-
strated in high risk symptomatic cardiac patients (). e CASS study also showed
a  increase in overall survival in asymptomatic patients treated for proximal left
CAD (). In our patients, all significant stenosis were located in the ostium or prox-
imal in the coronary arteries, resulting in a large cardiac area at risk at the event of
occlusion.
Screening and cardiac intervention in asymptomatic HL survivors might there-
fore also be indicated, but this should be evaluated in larger cohort studies, as it is
unlikely that randomized trials will be feasible in this setting. Our study showed that
acceptance of screening was high. Regardless whether CTA showed abnormalities or
not,  was content with the screening study and with being informed on the risk
of late cardiac events. In view of the broad acceptance of screening and the high rate
of CAD stenoses found in this phase II study, a nationwide study to establish the role
of CTA-based cardiac screening in a large population of asymptomatic HL survivors
treated with mediastinal radiotherapy should be considered. is could also provide
more clarity on timing and frequency of screening, costs of screening and possible
effects of screening on HRQL. Positive findings of screening should also be balanced
against possible disadvantages such as additional radiation exposure and the risk of
complications due to invasive diagnostic procedures.
At LUMC β-blockers are given prior to CTA imaging to optimize image quality.
However, a remarkably large proportion of the participants () had elevated heart
rates unresponsive to β-blocking agents.is led to non-evaluableCTA scans in three
patients, and suboptimal quality images in another  patients. Further research on
the pathophysiology of this tachycardia will be conducted.
In conclusion, prevalence of severe CAD in asymptomatic long-term HL sur-
vivors treated with mediastinal irradiation is significantly increased, and very often
asymptomatic, even in the presence of a severe proximal stenosis. is might justify
screening by CTA to reduce the risk of life-threatening cardiac events in this popu-
lation, but the role of CTA-based cardiac screening needs to be evaluated in larger
cohort studies.
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chapter 4
Impact of cardiovascular counseling and
screening in Hodgkin lymphoma survivors










L.V. van de Poll-Franse
Abstract
Purpose
Cardiovascular disease (CVD) is the most common nonmalignant cause of death in
Hodgkin lymphoma (HL) survivors, especially after mediastinal irradiation. e role
of screening for CVD in HL survivors is unclear, but confrontation with risks of CVD
may have a negative influence on health-related quality of life (HRQL). As part of a
phase II screening study using computed tomography angiography (CTA) amongHL
survivors, a HRQL analysis was done to evaluate the emotional and practical burden
and perceived benefits of screening and the effect of CVD-specific counseling on
patient satisfaction.
Methods
Patients who participated in the screening study took also part in the HRQL study.
e impact of undergoing screening was evaluated with a -item questionnaire, and
impact on HRQL with the EORTC QLQ-C. e effect of counseling on CVD on
perceived information provision was evaluated with the EORTC INFO-.All ques-
tionnaires were completed at baseline and after screening.
Results
Baseline questionnaires were received from  participants, and  completed ques-
tionnaires after screening.Mean agewas  years,mean time since diagnosis  years.
were contentwith participating, and did not find the emphasis placed on late
effects burdensome, although screening did have a small impact on social functioning
and global quality of life.
Perceived information on disease, medical tests and treatment increased sig-
nificantly after screening (p<.). Differences were clinically relevant. ere were
no differences in perceived information between patients with and without screen-
detected CVD.
Conclusions
Screening was evaluated favorably, whether CTA showed abnormalities or not. Ex-
tensive counseling resulted in substantially increased information provision, result-
ing in improved information satisfaction. Screening bymeans ofCTAand subsequent
cardiac intervention was highly valued and the benefits were felt to outweigh the









eoutlook for cure of Hodgkin lymphoma (HL) patients has improved dramatically
due tomodern chemotherapy and improved radiotherapy techniques (-). However,
over the past decade it has become evident that cure may come at a price. Epidemio-
logical studies have shown that survivors of HL are at serious risk for late treatment
effects, such as an increased risk of long-term risk of secondary cancers (, ). e
most common nonmalignant long-term complication of treatment inHL survivors is
cardiovascular disease (CVD).HL survivorswho hadmediastinal radiotherapy have a
- fold increased risk of myocardial infarction due to coronary artery disease (CAD)
(-). Even severe CAD is often not accompanied by symptoms, and can occur in
absence of traditional risk factors ().
e role of screening for radiation-induced CAD in HL survivors is unclear. Sev-
eral prospective studies have shown that screening asymptomatic HL survivors by
means of computed tomographic coronary angiography (CTA) yields high preva-
lence rates of CAD (-).
However, the benefit of screening on survival is unknown. Also, the perceived
burden and distress of undergoing screening, and the effect of cardiovascular coun-
seling on health-related quality of life (HRQL) have not been studied in HL survivors.
Confrontation with possible risks of disease may have a negative effect on psycho-
social well-being.is effect has been shown in screening programs for breast cancer
(). However, other studies have shown that empowering patients by improving
information provision and thus disease understandingmight actually improveHRQL
().
To investigate the role of CTA as a screening tool, we have conducted a phase
II screening study in asymptomatic HL survivors at risk for developing radiation-
induced CAD (). We included a HRQL analysis to determine the perceived burden
of screening, and evaluate whether extensive counseling on risks of CVD improved
perceived information provision and patient satisfaction.
Methods
Patients
e study protocol for this phase II screening protocol was approved by the Leiden
University Medical Center (LUMC) Ethics Committee and registered with Clinical-
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Trials.gov,NCT. Since  long-termHL survivors from regular follow-up
outpatient clinics at the Department of Radiation Oncology at LUMC are referred to
an outpatient clinic specifically designed for monitoring late effects of treatment of
HL. At this outpatient clinic two dedicated radiation oncologists and one hematol-
ogist counsel HL survivors who are at least  years disease-free after treatment with
respect to individual risks of late treatment effects, and provide standardized follow-
up care, including screening for breast cancer in female HL survivors.
To address the feasibility of cardiac screening by means of CTA and evaluate the
perceived burden and benefits of screening a phase II study was designed. Patients
attending the late effects outpatient clinic who were at least  years disease free
and had received mediastinal radiotherapy as part of their treatment, who were <
 years, and without current serious cardiac disease were eligible, and invited to
participate in the study.
Primary endpoint of the phase II study was the presence of significant CAD (>
 stenosis) on CTA. Patients with abnormal CTA scans subsequently underwent
diagnostic coronary angiography (CAG). CTA screening was considered to be indi-
cated for testing in a larger population if revascularization would be indicated in ≥
 of the patients undergoing CTA. Secondary objectives were to determine the
frequency and type of subsequent interventions, to evaluate satisfaction with infor-
mation provision and to determine the burden of the various aspects of screening
and the impact of specific counseling on CVD on HRQL.
Counseling, screening and assessment of HRQL
Participants in the screening study received specific, in-depth counseling on the
risk of developing radiation-induced CVD by a dedicated radiation oncologist. After
written informed consent, patients were referred to the cardiology outpatient clinic
where they received additional counseling and lifestyle advice to reduce the risk of
future cardiac disorders by a cardiologist. Subsequently an extensive cardiovascular
screening programwas performed.is included a resting electrocardiogram (ECG),
echocardiography and symptom-limited exercise ECG testing. CTA was performed
in a separate visit. After completing all tests, results and potential indications for
future analysis or treatment were discussed. Participation in the HRQL part of the
screening study was not mandatory for inclusion in the cardiac screening program.
For the HRQL part, patients were asked to complete three validated question-
naires at baseline and after discussing test results or subsequent interventions; a -
item screening-specific questionnaire was added to the end-of-screening question-








participate in the screening study and were returned prior to referral to the Cardi-
ology Department. End of study questionnaires were sent out - months after the
final visit to the Cardiology department.
Questionnaires
To evaluate the effect of cardiovascular counseling and screening on information pro-
vision the EORTC INFO- questionnaire was used. is module evaluates cancer
patient satisfaction with regard to information received in different areas of their
disease and treatment, and evaluates qualitative aspects (, ). e  items are
organized in four multi-item scales and single items. After linear transformation, all
scores range from - (). High scores mean a high level of information received
().
Global quality of life was assessed with the EORTC quality of life core question-
naire (QLQC- v.). All subscales and symptom responses from this questionnaire
are linearly converted to  to  scales (). A higher score for a functional or global
quality of life scale represents a better level of functioning.
Fatigue wasmeasuredwith the fatigue assessment scale (FAS); a validated  item
questionnaire reflectingmental and physical fatigue (, ).Total scores ranged from
 to . A higher score reflects a higher level of fatigue. A score over  points
indicates a substantial level of fatigue ().
Evaluation of screening
To evaluate the burden of the various aspects of screening, and determine satisfaction
with the screening procedures an additional short questionnaire containing  items
was designed (appendix). e first three questions evaluated the burden of the two
separate visits that weremade as part of the screening protocol, and the psychological
impact of waiting for test results. e emphasis placed on late treatment effects due
to screening might be perceived as distressing, which was evaluated in question .
e fifth question evaluated whether participants felt well informed with regard to
the purpose of the screening program. e last part of the questionnaire evaluated
patient satisfaction with several aspects of the screening study to assess whether
participants were sufficiently prepared for the procedures of the screening tests, and
were content with the aftercare. e final question evaluated satisfaction with par-
ticipating in the study in general.
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Statistical analysis
All statistical analysis were performed using SPSS statistical software for windows
version  (SPSS inc., Chicago, IL). Results of the evaluation of screening question-
naire and differences between participants with andwithout significant CADonCTA
were analysed using the χ test for trend.
e EORTC INFO- and QLQ-C questionnaires were analysed according to
EORTC guidelines (). For partially incomplete questionnaires imputation of the
mean was used for scales containing at least  of the scores ().
To test for significant changes in perceived information provision, fatigue or
global quality of life between start and end of the screening study, results were com-
pared using a paired t test. Clinical relevance of changes was defined according to
published guidelines. For the EORTC INFO- a difference in score ≥  points
indicates a clinically relevant difference (). Multivariate linear regression analysis
was performed to investigate independent associations between socio-demographic,
clinical characteristics and abnormalities on CTA with differences in perceived in-




In the screening study,  patients started the screening protocol between January
 and March . In total,  patients finished the screening protocol, all of
whom underwent CTA. One patient did not complete the screening protocol, due
to immediate intervention for severe aortic valve stenosis. Due to increased heart
rates resistant to beta blocking agents and resulting in motion artefacts on CTA, 
scans were not evaluable. In the  patients with evaluable CTA scans abnormalities
were found in  patients (), of whom  needed intervention ().
BaselineHRQLquestionnaireswere received frompatients starting the screen-
ing protocol (). End of study questionnaires were filled out by  patients ()








52 patients included 
Screening study QoL study 
56 patients eligible 
52 patients included 
48 finished screening 
protocol 
49 started screening 
protocol 
45 evaluable CTA 
56 patients eligible 
48/49 patients filled out QoL forms 
47/48 patients analyzed for QoL 
part of the study  
3 withdrew consent 
1 patient without 
CTA 
3 patients CTA poor 
quality 
1 patient no CTA, QoL forms 
separately analyzed 
43/47 patients filled out QoL forms 
at completion of screening protocol 
Figure 4.1: Consort diagram of screening study and quality of life study.
CTA scans did complete the entire screening protocol, they were included in the
HRQL analysis. e four patients who did not return end of study questionnaires
were two males and two females, all of whom had no abnormalities on CTA.
Returned questionnaires were complete for all items in  of the EORTC INFO-
,  of the EORTCQLQ-C,  of the FAS and  of the evaluation of screen-
ing questionnaire.
Mean age of participants of the HRQL study was  years, mean time since di-
agnosis was  years. Most patients () had been treated with combined modality
treatment, and  had received > mg/m anthracycline in their chemotherapy.
Most patients () had a high level of education, and  were currently employed
(Table .).
Table 4.1: Characteristics of health-related quality of life study participants
Number of patients %
Total 43
Sex Number of patients %
Male 16 37
Female 27 63
Age and time interval Years Range
Median age at diagnosis HL 26 15-37
Median age at time of study 47 29-60
Median time since diagnosis 21 11-29





Treatment Number of patients %
Median dose mediastinal radiotherapy (range) 36 (24-40)
Number of patients receiving combined modality treatment 30 70
Number of patients receiving >300 mg/mm2 anthracycline 7 16
Marriage status Number of patients %
Single 3 7
Living with partner or married 36 84
Living with other family/children 4 9








Cardiovascular risk factors Number of patients %
Current cigarette smoking 3 7
Hypertension 4 9
Diabetes mellitus 0 0
Dyslipidaemia 3 7
Family history positive for myocardial infarction 7 16
Body mass index >25 16 37
* Education levels: low = none/primary school, intermediate = lower general secondary education / vocational training, high =
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Figure 4.2: Patient responses to evaluation of screening questionnaire regarding practical aspects and
perceived burden. A/B represent the results of the first five questions evaluating satisfaction with several
aspects of the screening protocol, both fot the total group (A) and split by group of patients with and without
abnormalities on CTA (B). C/D represents the perceived burden of various aspects of the screening program,
both for the total group (C) and seperately for patients with and without abnormalities on CTA (D).
Evaluation of screening
Visiting the outpatient Cardiology clinic was perceived as not or a little bothersome
by  of the participants. Undergoing CTA was perceived as bothersome by ,
and  felt nervous before receiving the test results. Overall,  did not perceive
the emphasis that was placed on possible late cardiac effects of treatment for HL by
this screening study as bothersome (Figure .A+C).
Patient satisfaction with participating in the screening study was high;  felt
they were well informed about the purpose of the study, and  were content with
the practical affairs concerning the study. Although  were satisfied with infor-
mation and explanation of test results,  felt follow-up care should be improved.
Overall,  were highly satisfied with participating in the study (Figure .A+C).
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Differences in the evaluation of screening questionnaire between participants
with and without abnormalities on CTA were small and not statistically significant.
However, patients with abnormal CTA scans more often answered the question
“how distressing is the emphasis placed on late effects” with “quite a bit” than partic-
ipants with no abnormalities ( vs , p=., Figure .D).
Information provision and satisfaction, fatigue and global QoL
Results of the EORTC INFO- questionnaire showed that levels of information
provision increased over time. Perceived levels of information concerning disease,
medical tests, information on treatment and on other services such as possibilities
for professional support were all significantly increased after completing the screen-
ing protocol, as compared to baseline (Figures .A-D). Mean differences in scores
between baseline and after screening were  (SD ) points for information on
disease,  (SD ) points for information on medical tests and  (SD ) points
for information on treatment, indicating a substantial clinical relevance. Although
the increase in perceived information on other services was less pronounced (from 
to  points, Figure .D), the difference was also clinically relevant.
Satisfaction with received information increased significantly from  to 
points (p<.), a clinically relevant difference. Usefulness of given information also
increased significantly, from  to  points (p<.).
erewere no differences in levels of fatigue before or after the screening protocol
(mean levels  points vs.  points, respectively). e number of patients indicating
a substantial level of fatigue slightly increased from  () to  (). e two
new fatigue cases both had screening tests without abnormalities.
Results from the EORTC QLQ-C questionnaires are presented in Table ..
Role, physical, cognitive and emotional functioning did not change significantly over
time. A small decrease in global health, from  points to  points, was found. e
largest decrease was found in social functioning, from  points before screening to
 points after completion, which reflects a small, clinically relevant difference.
Multivariate regression analysis did not show any significant associations be-
tween age, gender, level of education or abnormalities on CTA and perceived level of










































































































p < 0.01 p < 0.01
p < 0.01 p < 0.01
Figure 4.3: Patient responses to EORTC INFO-25 questionnaire. Mean levels of perceived information on
disease (A), medical tests (B), treatment (C) and on other services (D) before start and after completing the
screening program. A higher score indicates a higher level of perceived information. Error bars represent the
95% confidence intervals.
Table 4.2: Health-related quality of life and fatigue scores
Before screening After screening P-value Clinical relevance
Mean SD Mean SD (23, 25)
QLQ C30
Functional scales
Role functioning 82 25 82 25 0.76 n.a.
Physical functioning 89 16 87 20 0.21 trivial
Cognitive functioning 84 21 82 21 0.43 trivial
Emotional functioning 81 18 82 21 0.73 trivial
Social functioning 88 20 82 27 0.03 small
Global health 76 20 72 20 0.04 small
FAS
Total fatigue score 21.0 7.6 21.3 7.7 0.60 no
Results of the functional scale and global quality of life scores from the EORTC quality of life core
questionnaire (EORTC QLQ-C) and scores from the Fatigue Assessment Scale (FAS) both
before and after screening.
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Discussion
is analysis evaluated an extensive counseling and screening programme amongHL
survivors at risk for long-term cardiac sequelae of mediastinal radiotherapy, and as-
sessed the effect on perceived information provision and satisfaction. Key findings of
this study were that evaluation of screening was favorable, and did not differ between
patientswith andpatientswithout abnormalities on the screening tests. Furthermore,
perceived levels of information on disease, medical tests and treatment increased
after counseling and completing the screening program, resulting in significantly
improved satisfaction with information provision. Benefits of screening were felt to
outweigh the burden.
Although several screening studies for radiation-induced cardiac disease have
been performed, our study is the first to evaluate the psychological impact of car-
diac screening on HL survivors, to assess the effect of counseling and screening on
perceived information provision, and the first to evaluateHRQLboth before and after
screening (-). We showed the emphasis placed on possible late cardiac disorders
due to treatment was not perceived as burdening. In fact, screeningwas highly valued
by almost all participants in our -item specific questionnaire, thus indicating that
perceived benefits outweigh the burden of screening, both in practical and emotional
sense. Results from the validated QLQ-C questionnaire confirmed these results,
showing no decrease in the emotional, cognitive or role functioning scales. However,
counseling and screening did have a small impact on social functioning and perceived
global health. We also showed that the combination of extensive information pro-
vision and screening translates into a clinically relevant improvement in perceived
information and increased satisfaction with information provision. e difference
found in the subscale ‘information on other services’ increased significantly after
screening, but mean scores were still low. is could be explained by the fact that
this aspect of information contains services such as information distributed on video
or professional psychological support, which was not the main focus of the current
study. Concerning fatigue and global quality of life, we found no significant differ-
ences between start and end of the study. is is not unexpected, considering the
relatively short time interval in which the screening took place.
Eligible patients for this study were selected from the current follow-up popu-
lation of HL survivors. Due to the increased risk of breast cancer prompting active
screening, a large part of this population consists of females. is could explain the
high percentage of female participants. Initially, almost all patients who participated
in the screening protocol filled out baseline questionnaires. Compliance was high, as








missing items was limited. erefore, the chances that the results were influenced by
drop-out bias are small.
To evaluate whether the results of the cardiac tests influenced perceived informa-
tion provision, fatigue or quality of life, multivariate regression analysis with a limited
number of patient- and clinical variables and with CTA outcome was performed. No
significant associations were found. However, the total number of patients in our
analysis is small, thus limiting the possibilities for robust analysis between the two
groups. Descriptive analysis of differences in evaluation of screening mostly showed
similar results for patients with or without abnormalities on CTA as did satisfaction
with various aspects of the screening. However, patients with abnormal CTA scans
did report the emphasis placed on late effects as being burdening more often than
patients without abnormalities.ey also reported to bemore nervous about the test
results. Since the second set of questionnaires were sent out after patients finished
the screening program and possible subsequent interventions, answers to both these
questions could have been influenced by the result of the tests.
e role of cardiac screening in patients treated for HL is unclear. Previous
screening studies have shown that prevalence of CAD detected by CTA in HL sur-
vivors is high (, ). Our phase II screening study did not only show a high preva-
lence of abnormalities on CTA in asymptomatic patients, but majority of these pa-
tients also underwent subsequent interventions.
Screening might be advisable, provided that a treatment improving outcome is
available for patients with screen-detected abnormalities. Survival benefit of cardiac
interventions has been demonstrated in high risk symptomatic cardiac patients ().
Whether a similar benefit can be achieved in asymptomatic HL survivors is as yet
unknown. Aspects of screening such as cost-effectiveness, patient compliance and
perceived burden and benefits of screening are of critical importance. Our analysis
showed that the psychological impact of confrontation with possible late treatment
sequelae does not seem to impede willingness to participate in screening, nor does it
seem to influence satisfaction with participation.
In conclusion, in addition to a high prevalence rate of cardiac abnormalities and
subsequent interventions in asymptomatic HL survivors after mediastinal radiother-
apy, we have shown that the perceived burden and benefits result in a favourable
patient evaluation of screening. Moreover, extensive counseling and comprehensive
screening resulted in substantially increased information provision.
A positive effect of screening should be confirmed in a larger scale study. How-
ever, whether it proves to indicated or not, screening by means of CTA and subse-
quent cardiac intervention is highly valued and not considered an extra psychological
burden.
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Appendix: Evaluation of screening questionnaire
e following questions specifically address your visit to the Cardiology Outpatient
Clinic and the CT-scan that was performed. Please answer the questions by circling
the number that best applies to you. ere are no ‘right’ or ‘wrong’ answers. e
information that you provide will remain strictly confidential.
Not at all A little Quit a bit Very much
1) How burdensome was the visit to the Cardiology outpatient clinic
for you?
1 2 3 4
2) How burdensome was it for you to undergo the CT scan? 1 2 3 4
3) How nervous were you about receiving the test results? 1 2 3 4
4) How distressing is the emphasis that is placed on possible late side
effects of your treatment to you?
1 2 3 4
How satisfied are you with: Not at all A little Quit a bit Very much
5) the information that was given to you concerning the purpose of this
screening study?
1 2 3 4
6) the explanation given to you concerning the practical affairs of this
screening study?
1 2 3 4
7) the explanation given to you concerning all test results? 1 2 3 4
8) the follow-up care after finishing all tests? 1 2 3 4
9) participating in this study? 1 2 3 4
chapter 5
Persisting fatigue in Hodgkin lymphoma
survivors: A systematic review








Hodgkin lymphoma (HL) survivors are at risk for adverse psychosocial events as a
result from cancer diagnosis and treatment. Fatigue is one of the most frequently
reported long-term symptoms and is often reported to interfere with daily life. We
conducted a systematic review to determine prevalence, severity and predisposing
factors of fatigue in HL survivors.
Methods
A literature searchwas conducted up toAugust . Twenty-two articles comparing
HL survivors with norm population data met all predefined selection criteria. Preva-
lence rates, levels of fatigue and clinical relevance of the results were determined.
Results
Prevalence of fatigue ranged from - in HL survivors compared with  in
the general population. Mean fatigue scores were - higher compared with the
normative population; these findings were clinically relevant in  out of  studies.
Increasing agewas associatedwith higher levels of fatigue inHL survivors. Treatment
modality and stage of initial disease were not associated with higher fatigue levels,
while comorbidities or other treatment sequelae seemed to impact on the levels of
fatigue.
Conclusions
HL survivors are at serious risk for developing clinically relevant, long-term fatigue.
e impact of patient- and treatment characteristics on risk of fatigue is limited.










Hodgkin lymphoma (HL) is a relatively rare form of cancer. HLmainly affects adoles-
cents and young adults. Significant therapeutic improvements have resulted nowa-
days in a favorable prognosis with an overall -year cancer-specific survival rate of
 (). e combination of highest incidence at a young age and improved survival
has, however, led to an increasing number of HL survivors, who remain at risk for
long-term complications of their treatment. Many studies have focused on adverse
physical effects of treatment, such as an increased risk of secondary tumors (, ) or
cardiovascular events (, ). Since the s, studies have increasingly been focused
on psychosomatic and psychosocial aspects of treatment and on the burden of having
survived cancer. Fatigue is one of the most frequently reported symptoms among
(long-term) survivors of HL (-). It is a main component of the multidimensional
concept of health-related quality of life (HRQL). Fatigue and associated symptoms
such as lack of energy or loss of vitality are among the symptoms rated most often
as interfering with daily life. It has been reported to have a significant impact on
perceived HRQL, even more so than some specific physical symptoms like nausea or
pain (). Fatigue itself has therefore been addressed in several studies, either briefly
when measuring general HRQL in HL survivors, or more explicitly in studies using
specifically designed and validated fatigue questionnaires.Most of these articles have
also investigated the relation of fatigue with patient- and treatment-related factors.
Since many of these studies were cross-sectional by design, their findings merely give
an indication of possible associations, and their findings were often contradictory.
e purpose of this review was to provide a comprehensive overview of studies
which have investigated fatigue in HL survivors, focusing on the prevalence and
severity of fatigue and on associations between patient- and treatment-related
factors and levels of fatigue.
Methods
Literature search strategy
A literature search was performed for all articles up to August  using the elec-
tronic databases of Web of Science, PubMed en PsychINFO. Key terms used in
the search were ‘Hodgkin’, ‘Hodgkin’s’ and ‘Hodgkins’ in combination with ‘(Health
related) Quality of Life’, ‘Value of Life’, ‘Fatigue’, ‘Energy Level’ or ‘Vitality’. Lists of
references were verified to find additional publications that were not found by the
computerized search.
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Selection criteria
e literature search resulted in  hits, of which  were duplicates. A total of
 were excluded based on title. Of the  abstracts retrieved,  were selected
for full text review. Selection of articles was based on English language and measure-
ment of fatigue by generic and/or fatigue-specific questionnaires. Abstracts, studies
conducted before , studies combining results of more than one type of tumor, or
addressing fatigue in a specific subgroup of patients such as those who had intensified
treatment for relapsed or refractory HL, were excluded. Subject of the studies had to
be either comparison of fatigue inHL survivors with a well-defined norm population,
and/or analysis of the relationship of fatigue with patient- and treatment character-
istics. Specific focus was placed on the relationship between late-treatment sequelae
or comorbid conditions and fatigue.
A total of  articles met the described selection. Six (-) review articles were
further excluded since they only briefly discussed fatigue, and did not contain any
additional studies to the remaining  original articles.
Quality assessment
emethodological quality of the selected articles was defined by scoring items from
a standardized checklist with predefined criteria. ese criteria originated from an
established criteria list for systematic reviews that was previously used (-) which
was slightly adapted for the purpose of this review. e criteria are listed in Table ..
For every one of the criteria that was met, one point was assigned to the study. In
case of absence of an item, zero points were assigned. erefore, a total number
ranging from  to  points per study was assigned to each study. A higher total score
indicates a higher quality assessment. Studies scoring  (≥ points) or more were
considered as ‘high quality studies’. A score between  and  was considered to
be moderate and studies scoring less than  were qualified as ‘low quality’.
e evaluation of the methodological quality of studies was done separately by
LAD and SO. A consensus meeting was held to discuss differences between the two
reviewers and a consensus score was assigned.
To determine clinical relevance of reported differences in mean fatigue scores for
studies comparing HL survivors to a norm or control group we used the following
guidelines. For the European Organisation for Research and Treatment of Cancer
Quality of LifeQuestionnaire (EORTCQLQ-C) differenceswere defined according
to the EORTC guidelines as trivial (- point difference), small (- point difference)







Table 5.1: Criteria for assessing the methodological quality of studies of fatigue in HL survivors*
Quality of life assessment
1. a validated fatigue specific or generic HRQL questionnaire measuring fatigue or vitality is used
(e.g. FQ, SF-36, EORTC QLQ-C30)
Study population
2. a description is given of at least two socio-demographic variables
3. a description is given of at least two clinical variables
4. in- and exclusion criteria are described
5. response rate to the QoL or fatigue questionnaire is ≥ 65%
6. information is provided on differences of characteristics between responders and non-responders
7. time since diagnosis is provided
Study design
8. the study size consist of at least 50 participants
9. data are prospectively gathered
10. the process of data collection is described
11. missing data are described
Results
12. the results are compared between two groups or more (e.g. healthy population, groups with
different treatment or age and/or compared with at least two time points)
13. mean, median, standard deviations or percentages are reported for the most important clinical
outcome measure
14. statistical proof for the findings is reported
* adapted from (16-18).
Abbreviations: HRQL = health-related quality of life; FQ = Fatigue questionnaire; SF-36 = short form 36; EORTC QLQ-C30 = European
Organisation for Research and Treatment of Cancer Quality of Life questionnaire.
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points differencewas considered clinically relevant (). For the other questionnaires,
Norman’s ‘rule of thumb’ was used, whereas a difference of > . SD indicates a
discriminating change in fatigue scores ().
Results
Study characteristics
All  identified studies had been published between  and . Seven studies
focused specifically on fatigue (-); while in the other  fatigue was measured
and reported as part of the assessment of HRQL (, , -).
Two studies had a prospective, longitudinal design (, ). Both of these studies
were HRQL protocols associated with large multicentre clinical randomized trials,
comparing different treatment strategies. Eighteen studies had a cross-sectional de-
sign, either in a single center (, -, , , , -, , ) ormulticenter setting
(, , , , ). Two studieswere follow-up studies of earlier cross-sectional reports
(, ).
In  of the  cross-sectional studies, HL survivor fatigue levels were compared
with data from a general norm population (, , , -, , ) or to matched
cases (, , , ). e remaining six described fatigue within a HL survivor cohort
and were selected because they explored associations between fatigue and patient-
or treatment parameters. e total number of patients included in all studies ranged
from  () to  (), and median time since diagnosis ranged from  months ()
to  years ().
Of all  studies,  reported on associations of clinical and/or treatment charac-
teristics with higher levels of fatigue (, , -, -, , -).
e validated questionnaires thatwere used in the studies eithermeasured fatigue
specifically (Fatigue questionnaire (FQ) (), Multidimensional Fatigue Inventory
()), (, , , , ), or measured fatigue as a scale of a generic or cancer-specific
HRQL questionnaire (Short Form  (SF-) (), EORTC QLQ-C ()), (, ,
, , , , -, ). e SF- addresses fatigue and energy by measuring a
four-item vitality scale, the EORTCQLQ-Cmeasures a separate three-item fatigue
scale. Questionnaires less often used were the Profile of Mood States (POMS()),
the Functional Assessment of Chronic Illness erapy-Fatigue (FACIT-F ()) and
the Schedule for the Evaluation of Individual QoL-Direct Weighting (SeisQoL-DW









Seven studies reported prevalence rates of fatigue, ranging between  and 
(see Tables . and .). However, five of these seven studies reported on the same
Norwegian HL survivor cohort, measured at two time intervals. As a result, they
reported similar fatigue prevalence rates, defined as a dichotomized score of  out
of  questions in the FQ, of  (measured in , (-)) and  (measured in
, (, )). Rates of fatigue in theHL survivor cohort (-) in these five studies
were significantly higher than the  fatigue that was measured in the population
survey (, , ).
Two studies reported on other cohorts of HL survivors. One () reported a
prevalence of at least some level of fatigue in  of  HL survivors, using a score
of≥  out of a possible  in the EORTCQLQ-C as cut-off.e other () found
that  of  HL survivors self-indicated fatigue as an area importantly affected by
HL diagnosis and treatment.
Fatigue scores
Sixteen studies reportedmean fatigue scores in HL survivors (see Tables . and .).
Among the  studies that compared mean fatigue scores to a norm population or
a set of matched cases, the two smallest case-control studies did not find significant
differences in levels of fatigue (, ). e remaining  studies all showed statis-
tically significant higher fatigue scores in HL survivors compared with norm data
(, -, -, , ). Only two of these studies addressed the clinical relevance
of higher fatigue scores in HL survivors by reporting effect size. Hjermstad et al.
() reported an effect size of . measured by FQ, which was defined as moderate,
and Loge et al. reported a small effect size of . measured by SF- (). Overall,
differences in fatigue scores betweenHL survivors and normative populations ranged
from -. ree studies used the EORTC QLQ-C questionnaire, of which two
measured a difference of . points (.), compared with the general population
(, ). Brandt et al. () found a difference of  points () in fatigue scores on
the QLQ-C between HL patients treated with chemotherapy alone, and a German
reference population. Two studies reported on vitality scores using the SF-, and
found differences of  and , respectively (, ). ree studies used the FQ
for assessment of fatigue. All of these studied the same HL cohort (at two different
time intervals) and used a general practitioner survey for norm data, and reported
differences in fatigue scores of - (, , ).











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.4: Association of patient, clinical and treatment characteristics with observed fatigue
Variable No. of studies with positive
relation / total no of studies
investigating variable
No. of subjects with positive




Age* 4 / 7 2332 / 3255 Increasing fatigue with older age
Sex* 2 / 7 977 / 3212 935 female more fatigue, 42 male more
fatigue
Education* 1 / 2 459 / 970 More fatigue in lower educated
Systemic symptoms* 2 / 5 1771 / 2891 More fatigue if systemic symptoms
present at diagnosis
Stage* 0 / 5 0 / 2200 No influence of stage on fatigue
Treatment* 2 / 11 380 / 3955 More fatigue after combined modality
treatment
Time since diagnosis* 4 / 7 1479 / 2942 1311 decrease of fatigue over time, 168
increase of fatigue over time
Relapse* 1 / 4 836 / 1991 More fatigue after (treatment for) relapse
Smoking 1 / 2 511 / 1347 More fatigue in smokers
Psychiatry 2 / 2 932 / 932 More fatigue in patient with psychiatric
comorbidity
Late complications 3 / 3 771 / 771 More fatigue in presence of late
complications/comorbidity
* exclusion of overlapping results from studies reporting on the same HL cohort
) did not report precise levels of fatigue, but reported on the course of fatigue over
time, both showing decreasing fatigue over time after completion of treatment. Ganz
et al. () showed a decrease of fatigue from  months after diagnosis, with fatigue
levels returning to baseline level at two years after diagnosis.
Socio-demographic, clinical and treatment characteristics associated
with fatigue
Among the  studies,  studied fatigue in relation to socio-demographic, clinical,
or treatment-related characteristics. An overview of these characteristics and their
association with fatigue is presented in Table .. Overlapping results from studies
reporting from the same HL cohort were excluded. Variables that were most fre-
quently associated with fatigue were gender, age, stage of HL, treatment, time since
diagnosis and occurrence of relapse (, , -, -, , -).
Seven studies examined the association of gender and levels of fatigue. Five stud-
ies found no relationship (, -, ), while one large longitudinal study showed
that women had statistically significant worse scores of fatigue as measured by
EORTC QLQ-C and general fatigue as measured by the MFI, but failed to show a
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relation between gender and the other fatigue dimensions of theMFI (). In contrast,
in a study of  HL survivors Norum et al. found that men had worse outcomes in
fatigue scores than women ().
Four out of seven studies found significantly higher fatigue levels in older patients
(, , , ), while three other studies did not confirm this (, , ). None of
the five studies relating initial stage of HL to levels of fatigue found a significant
association (, , , , , ).
Eleven studies have investigated fatigue levels with different treatment strategies,
such as radiotherapy versus chemotherapy or combined modality treatment. Nine
of these studies, all cross-sectional in design, did not find any relationship (, -
, , , -). One longitudinal study did report higher fatigue levels with com-
bined modality treatment  months after diagnosis when compared with radiother-
apy alone, but differences between treatment arms disappeared over a longer time
period and were most likely related to differences in duration between the two treat-
ment arms (). One cross-sectional study found higher fatigue scores after combined
modality treatment when compared with chemotherapy or radiotherapy alone ().
Time since diagnosis was examined in  studies. In four studies, time since diag-
nosis was associated with fatigue; one cross-sectional study showed higher fatigue
prevalence rates over time () while  longitudinal studies and  cross-sectional
study showed decrease of fatigue over time (, , ). ree studies did not find
any relation between time since diagnosis and fatigue (, , ).
ree out of four studies did not find an association between occurrence of re-
lapse and fatigue (, , ).One foundhigher levels of fatigue after relapse of disease
(). Other parameters, such as level of education or smoking were less frequently
investigated and mostly showed conflicting results.
Conflicting data concerning variables associated with fatigue could not be ex-
plained by differences in length of follow-up duration or instruments used.
Late treatment sequelae or comorbidities and fatigue
ree cross-sectional studies focused specifically on the impact of late-treatment
sequelae or comorbid conditions on levels of fatigue (, , ). Ng et al. com-
pared  HL survivors with  siblings (). ey observed a modest difference
in mean fatigue scores measured by the FACIT-F, and in multivariate analysis found
a significant positive correlation of cardiac disease with fatigue. ey did not find an
association between adequately suppleted hypothyroidism and fatigue. In their 
follow-up study among the HL survivors, they showed a statistically significant wors-








complications (). Knobel et al. () found higher levels of fatigue in HL survivors
suffering of pulmonary dysfunction, and confirmed absence of higher levels of fatigue
in survivors with treated hypothyroidism. However, they did not find an association
between fatigue and cardiac disease.
Miltenyi et al. () found higher fatigue levels in HL survivors with late treatment
complications in general.
Discussion
is systematic review, including  large studies that investigated prevalence of
fatigue or fatigue levels in HL survivors, showed prevalence rates of - in HL
survivors, compared with  in the general population.We also found - higher
levels of fatigue in HL survivors when compared with the general population; differ-
ences that were mostly clinically relevant. ere was some evidence that older age at
diagnosis might lead to higher fatigue levels. Treatment modality and stage of initial
HL did not seem to be associated with fatigue levels. Evidence for the influence of
characteristics such as level of education, time since diagnosis, or relapse of disease
was often contradictory.
Although HL is a relatively rare disease, its occurrence at a young age and the in-
creasing numbers of long-term survivors reporting long-lasting fatigue and reduced
vitality have prompted specific studies of fatigue among HL survivors. For  of the
 included studies, (, , -, , , , ) quality assessment scores ranged
from  to , indicating a high methodological quality. Shortcomings were mostly
lack of description of missing data (N=) and lack of description of non-responders
(N=). e latter makes it more difficult to estimate potential selection bias. Another
frequent shortcoming was lack of a prospective design (N=).
e majority of the studies were cross-sectional by design, which makes them
suitable for evaluating prevalence rates of fatigue, but limits the possibility to evaluate
causal relationships between prognostic factors and fatigue. Reported associations
were often contradictory, with the exception of the consistent finding that initial stage
of HL did not impact fatigue rates.
Only two studies had a prospective, longitudinal design. Both studies showed a
decrease in levels of fatigue over time. Ganz et al. () showed that fatigue levels in
both treatment arms, measured by the SF-, returned to baseline levels measured
before start of treatment. ese baseline levels, however, were lower than population
fatigue levels measured by SF- in other cross-sectional studies (, , ), both in
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HL survivors and in norm populations. is could be due to a patient selection bias,
since the study accompanied a randomized trial on efficacy of different treatment
strategies.
Concerning influence of treatment modalities on reported fatigue in these lon-
gitudinal studies, one study did not find different levels of fatigue between the two
different treatment arms, while the other did. is may be due to the fact that fatigue
was measured at a fixed time point of  months after diagnosis, without accounting
for the difference in treatment duration between the radiotherapy alone group and
the combined modality group. Twelve of the  cross-sectional studies addressing
treatment modalities found no association with levels of fatigue. Although treatment
modality may not have a direct impact on the risk of chronic fatigue, late treatment
sequelae may. Research on associations between fatigue and comorbidities or late
treatment complications is limited. A relation was suggested in three cross-sectional
studies. However, only one of these studies compared the results for HL survivors
with comorbidities to matched case controls. Levels of fatigue may also be negatively
influenced by the presence of depression, since presenting symptoms may overlap
between these conditions. ere was only one study that combined measurement of
fatigue and depression in a group of  HL survivors and found significant overlap
().
When we limit the evaluation of prognostic factors to the studies with the high-
est quality scores (, , , , , , , ), influence of patient and treatment
characteristics on levels of fatigue seems to be limited to increasing age.
Definition of fatigue is difficult and often subjective. erefore, measurement of
fatigue varies greatly between studies. It is often addressed through a variety ques-
tionnaires. It is unclear how these questionnaires correlate and if they would iden-
tify the same fatigue cases. Also, the interpretation of differences in fatigue scores
between patients and norm populations remains difficult. Statistically significant
differences do not necessarily imply clinical relevance. It was possible to determine
clinical relevance of reported differences in fatigue levels betweenHL and population
controls for  studies, of which  confirmed a clinically relevant higher fatigue score
in HL survivors. ese findings are in line with clinical practice, where a majority of
theHL survivors report to suffer from the effects of chronic fatigue in their daily lives,
while lack of clear predisposing factors limit treatment options. Optimal treatment
of comorbidities and especially of anxiety and depression might be of benefit.
In conclusion, HL survivors are at serious risk for developing chronic fatigue
and loss of vitality, since all except the two smallest studies showed - higher
prevalence rates of fatigue compared with population controls. Most studies showed
clinically relevant differences. Solid evidence for the influence of prognostic factors








seem to play an important role in the development of chronic fatigue. To be able
to provide a clinically meaningful treatment option for the chronic fatigue in HL
survivors, focus should switch to the role of comorbidities, late treatment sequelae
and the influence of psychological distress on developing fatigue in long-term HL
survivors, preferably by assessing longitudinal data on HL survivors compared with
a matched norm population.
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chapter 6
Chronic fatigue in Hodgkin lymphoma survivors
and associations with anxiety, depression and
comorbidity





L.V. van de Poll-Franse
Abstract
Purpose
Fatigue is a frequent and persistent problem among Hodgkin lymphoma (HL) sur-
vivors. We investigated the prevalence of clinically relevant fatigue in HL survivors
and the relation between fatigue and anxiety and depression.
Methods
Fatigue was measured through the generic European Organisation for Research and
Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C) and Fatigue
Assessment Scale (FAS). Anxiety and depression were measured with the Hospital
Anxiety and Depression Scale (HADS). Questionnaires were mailed to  HL sur-
vivors. Results were compared with a Dutch age-matched normative population.
Results
Response rate was  (median age  years, mean time since diagnosis . years).
Prevalence of fatigue was significantly higher among HL survivors than in the norm
population (FAS  vs , QLQ-C  vs ), as were fatigue levels.ere was
a significant association between fatigue, anxiety and depression. Of theHL survivors
with high symptom levels of depression,  also reported fatigue. In multivariate
analysis, depression was strongly associated with high levels of fatigue and, to a lesser
extent, anxiety and comorbidity.
Conclusions
Prevalence rates of fatigue are significantly higher in HL survivors than in the gen-
eral population and differences are clinically relevant. Depression and anxiety were
strongly associated with high levels of fatigue. Reducing fatigue levels by treatment









Over the past decades, survival of Hodgkin lymphoma (HL) patients has improved
dramatically with -year overall survival rates ranging from  to  (, ). is
has mainly been due to the introduction of multi-agent chemotherapy and improved
radiotherapy techniques. However, with improved life expectancy, patients often face
long-term effects caused by their treatment, such as treatment-induced secondary
tumors or cardiovascular disease (-).
Apart from these adverse physical effects, many HL survivors also report suffer-
ing from long-term psychosomatic and psychosocial problems (-). A number of
studies have focused on these psychosocial issues in HL survivors, mainly address-
ing overall health-related quality of life (HRQL). A recent review of HRQL in HL
survivors showed persistent problems in physical, role-physical, social and cogni-
tive functioning (). ese problems were most prevalent in HL patients treated
with combined modality treatment, in women and in patients of older age. Further-
more, a number of studies have focused specifically on fatigue, because this is one
of the most frequently reported and most persisting symptoms in HL survivors, and
has consistently been reported to have significant impact on HRQL (, -). e
mechanism that causes fatigue is largely unknown. Associations between fatigue and
clinical or patient characteristics have been made, mainly focusing on the influence
of treatment, time since diagnosis and age. However, such studies have provided
conflicting results (, -). e impact of comorbid conditions, whether or not
caused by cancer treatment, on perceived fatigue has been studied less frequently.
All conducted studies reported increased fatigue in HL survivors with comorbidities
(-).Of these studies, onlyNg et al. compared their resultswith a normpopulation
consisting of a group of siblings. Fatigue in the HL survivors was more frequent and
was associated with the presence of cardiac disease.
Fatigue is reported to be a frequent symptom of depression. Few studies have
explored the relationship between fatigue and depression in HL survivors. Loge et
al. reported increased levels of psychological distress in nearly  of fatigued HL
survivors; however, no comparison with a norm population was made (). Ng et al.
found that having a psychiatric condition was a significant variable for increased
fatigue (). Because of high prevalence rates of fatigue in the general population,
results on fatigue surveys of cancer survivors should be interpreted with caution and
be compared with an age- and sex- matched norm population.
e purpose of this study was to investigate the prevalence of clinically relevant
fatigue in HL survivors in the Netherlands compared with an age- and sex-matched
Dutch population, and to determine the relationship between fatigue and depression,
and other comorbid conditions.
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Methods
HL survivors
A cross-sectional survey was conducted at the Eindhoven Cancer Registry (ECR)
among HL survivors. e ECR records data on all newly diagnosed cancers in the
southern part of the Netherlands, an area with . million inhabitants,  hospital
locations and  large radiotherapy institutes. e ECR was used to select all patients
who were diagnosed with HL between January st  and December st . De-
ceased patients were excluded by linking the ECR database with the Central Bureau
for Genealogy. Hodgkin lymphoma survivors were contacted by mail through their
physicians and were asked to participate in this cross-sectional study by completing
and returning a set of questionnaires. In May , patients between  months and
 years after diagnosis received the first questionnaire. In November , patients
diagnosed between May  and May  were invited to participate and in May
, patients diagnosed betweenMay  andDecember were invited. Ethical
approval for this study was obtained from the University of Tilburg certified Medical
Ethics Committee.
Questionnaires
Survivors of HL were asked to complete the validated Dutch version of the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
(QLQ C-). e QLQ-C measures cancer specific HRQL and contains five func-
tional scales (physical, cognitive, emotional, social and role functioning), a global
health status/quality of life scale, six single items assessing additional symptoms and
three symptom scales (pain, fatigue and nausea/vomiting). For all items, Likert-type
response scales are used, with total scores per item ranging from  to  points. All
subscales and individual item responses are linearly converted to  -  scales ().
As a cutoff for fatigue caseness, we defined a score >. for the EORTC QLQ-
C although the fatigue symptom subscale has not been validated as a stand-alone
measure for fatigue (). For partially incomplete questionnaires imputation of the
mean was used for scales containing at least  of the scores (). Fatigue was also
measuredwith the FatigueAssessment Scale (FAS), a validated -itemquestionnaire
reflecting mental and physical fatigue (, ). Total scores range from  to , with
a higher score reflecting a higher level of fatigue. A score over  points indicates








Anxiety and depression were measured using the Hospital Anxiety and Depres-
sion Scale (HADS)(, ), whichmeasures levels of symptoms of anxiety and depres-
sion in two subscales of seven items each. A score >  on either subscale indicates
a possible caseness for an anxiety or depressive disorder; a score >  indicates a
probable caseness. For the HADS a score>  on either subscale was used as a cut-off
value for defining caseness of anxiety or depression, as this score achieves an optimal
balance between sensitivity and specificity (-).
Comorbidity was evaluated by the Self-administered Comorbidity Questionnaire
(). Education and marital status were also assessed in the questionnaire. Informa-
tion on tumor and treatment characteristics was available from the ECR.
Norm population
e norm population was selected from a reference cohort of approximately 
individuals from the general Dutch population (CentER panel ()). e set of ques-
tionnaires completed for this study included the QLQ-C, FAS and HADS ques-
tionnaires and also data on socio-demographics and comorbid conditions were pro-
vided. To compare the results with that of the HL survivor cohort, we made an age-
and sex-matched selection from this normative population. is reference cohort is
representative for the Dutch-speaking population in the Netherlands (, ).
Statistical analysis
All statistical analyses were performed using SPSS version  (SPSS inc., Chicago,
IL, USA). Patient, tumor and treatment characteristics between respondents, non-
respondents and patients with unverifiable addresses were compared using t-test
(numerical variables) and chi-square (categorical variables). A two-sided p-value <
. was considered statistically significant.
Differences between fatigue caseness from the EORTCQLQ-C and FAS and/or
caseness of anxiety or depression from the HADS in HL survivors and the norm
population, were calculated by chi-square tests.
Mean fatigue scores from the EORTC QLQ-C and FAS were compared be-
tweenHL survivors and the normpopulation using independent sample t-tests. Clin-
ical relevance of the differences was defined according to guidelines for the interpre-
tation of the EORTC QLQ-C () and according to Norman’s rule of thumb for the
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FAS, indicating a ± . SD difference of the norm in scores as a discriminating change
().
Multivariate logistic regression analyses using the dichotomous FAS score were
performed to analyze the association of socio-demographic, tumor, treatment and
comorbidity variables and fatigue. Variables were included into the model in sepa-
rate steps. Demographic variables were added first, then clinical variables and, third,
psychological distress. A two-sided p-value< . was considered statistically signif-
icant.
Results
Characteristics of the respondents and non-respondents
In total,  () of the  HL survivors completed and returned the question-
naires. Missing items on the completed questionnaires were < than  (N=). Re-
sponders were more often male and older than non-responders and than those with
unverifiable addresses (Table .). Mean time since diagnosis was . years; mean
age at the time of survey among HL responders was  years and  had received
combined modality treatment. Only  had been treated with radiotherapy alone.
ere were no statistically significant differences between HL responders and the
norm population concerning marital status or education (Table .). With regards
to comorbidities, HL responders less often reported hypertension ( vs ), but
more often thyroid disease ( vs ) and depression ( vs ) than the norm
population.
Fatigue prevalence and symptoms of anxiety and depression
ere were significantly more persons with fatigue among the HL survivors com-
pared with the norm population (Figure . and Table .). e QLQ-C fatigue
subscale identified a  prevalence of fatigue among the HL survivors, versus 
in the norm population (p=.). e FAS questionnaire showed fatigue prevalence
rates of  and of , respectively (p<.). Identification of fatigue cases was con-
sistent between the QLQ-C and the FAS questionnaire in  of the HL survivors







Table 6.1: Patient and treatment characteristics of the HL survivor cohort
HL responders Non-responders Unverifiable address P-value
N % N % N %
Total 180 35 52
Age at time of survey in years
Mean (SD) 46 (15.6) 40 (13.6) 40 (13.9) p=0.01
Range 19-84 21-79 20-83
< 40 75 41 18 51 34 65 p=0.02
40-60 70 39 14 40 14 27
> 60 35 19 3 9 4 8
Time since diagnosis in years
Mean (SD) 4.6 (2.9) 5.9 (3.2) 4.6 (3.0) p=0.07
< 5 102 57 14 40 29 56 p=0.11
5 - 10 76 42 19 54 23 44
> 10 2 1 2 6 0
Sex p=0.06
Male 99 55 23 66 37 72
Female 81 45 12 34 14 28
Stage at diagnosis p=0.60
I 31 17 7 20 9 17
II 94 52 14 40 19 37
III 26 15 6 17 12 23
IV 18 10 4 12 6 12
Treatment p=0.50
RT 6 3 0 1 2
CT 74 41 18 51 25 48
RT + CT 99 55 16 46 23 44
Abbreviations: HL = Hodgkin lymphoma; RT = radiotherapy only; CT = chemotherapy only; RT + CT= radiotherapy and chemotherapy.
Table 6.2: Characteristics of the study participants
HL responders Norm population P-value
N % N %
Total 180 327
Age at survey in years
Mean (SD) 46.1 (15.6) 48.8 (15.7) p=0.90
Range 19-84 20-85
< 40 75 42 117 36 p=0.28
40-60 70 39 129 39
> 60 35 19 81 25
Sex p=0.43
Male 99 55 168 51
Female 81 45 159 49
Self-reported comorbidity
Cardiac 17 9.4 21 6.4 p=0.07
Stroke 2 1.1 1 0.3 p=0.16
Hypertension 16 8.9 65 19.9 p=0.01
COPD 19 10.6 41 12.5 P=0.92
Diabetes Mellitus 8 4.4 25 7.6 p=0.39
Anemia 4 2.2 14 4.3 p=0.44
Thyroid disease 17 9.4 16 4.9 p=0.008
Depression 19 10.6 11 3.4 p<0.001
Comorbidity conditions p=0.37
No comorbidity 87 48 149 46
≤ 2 comorbidities 63 35 134 41
>2 comorbidities 21 12 44 13
Marital status p=0.62
Partner 133 74 252 77
No partner 44 24 75 23
Education level p=0.10
Low 14 8 13 4
Medium 107 59 191 58
High 56 31 122 37
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Figure 6.1: Prevalence of caseness of fatigue according to fatigue subscale of the European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QlQ-C30) and
fatigue assessment scale (FAS), and caseness of anxiety or depression according to the Hospital Anxiety and
Depression Scale (HADS) for both Hodgkin lymphoma survivors and the age- matched Dutch population.
The two last columns describe the prevalence of combined fatigue and anxiety or depression among all HL
survivors and of the norm population. * P < 0.05; ** P < 0.01.
levels of anxiety and  of depression, compared with  and  in the norm
population.
Of all responding HL survivors,  were identified both as a fatigue case and an
anxiety case;  were both fatigued and had symptoms of depression. ese num-
bers were significantly lower in the norm population (, p<. and , p=.
respectively, Figure .). e prevalence of fatigue among HL survivors with a high
symptom level of depression was , compared with  in the norm population.
Similar relationships were found for cognitive functioning (impairment of con-
centration and memory) and fatigue, with significantly lower social functioning and
especially lower cognitive functioning among HL survivors compared with the norm
population (see Table .). ere was a clear association between fatigue and cogni-
tive impairment. e mean scores of cognitive function were lower among fatigued
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Table 6.3: QLQ-C30, FAS and HADS mean scores for HL survivors vs norm population
HL Norm P-value Clinical relevance
Mean SD Mean SD (23, 32)
QLQ C30
Functional scales
Role functioning 83.8 24.4 89.6 20.0 p=0.05 Trivial
Physical functioning 87.1 15.7 90.9 14.8 p=0.08 Trivial
Cognitive functioning 82.5 22.0 92.5 15.7 p<0.001 Medium
Emotional functioning 82.4 22.9 87.9 17.8 p=0.03 Small
Social functioning 86.4 22.2 92.8 17.6 p<0.001 Small
Symptom scales
Fatigue 28.7 26.4 18.9 20.4 p<0.001 Small
Pain 13.0 22.4 14.2 20.9 p=0.54 Trivial
Nausea / vomiting 3.3 9.2 2.6 9.9 p=0.45 Trivial
Global Health Status 76.8 18.5 77.7 16.9 p=0.57 Trivial
FAS
Total fatigue score 21.4 7.6 18.4 5.8 p<0.001 Yes
HADS
Anxiety mean scores 4.7 4.2 3.8 4.3 p<0.001 No
Anxiety mean score in fatigue cases 7.6 4.5 6.5 4.0 p=0.31 No
Depression mean scores 3.7 3.8 3.4 3.2 p=0.02 No
Depression mean score in fatigue cases 6.6 4.1 6.4 4.0 p=0.83 No
Abbreviations: HL = Hodgkin lymphoma; EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire; FAS = fatigue assessment scale; HADS = Hospital Anxiety and Depression Scale.
HL survivors and fatigued participants of the norm population (. and . points
respectively) than in the non-fatigued participants (HL survivors . and norm pop-
ulation  points). Differences are clinically relevant in both groups, and reflect a
large difference in the HL survivors group and a medium difference in the norm
population.
Clinical relevance of fatigue scores
Fatigue scores were significantly higher among HL survivors than in the norm pop-
ulation, and these differences were clinically relevant (Table .). Mean QLQ-C
fatigue scores differed . points (. vs .), reflecting a small but clinically relevant
difference.e FAS total fatigue scores were . versus . points (>. SD), which








Association of fatigue with patient and treatment factors and comorbid
conditions
Multivariate regression analysis using the FAS scores showed that a lower level of
educationwas associatedwith a higher risk of fatigue (Table .). After adding clinical
variables to the regression analysis, the significance of level of education disappeared,
and having one to two comorbid conditions (OR.) or> than  comorbid conditions
(OR .) were significantly associated with fatigue.
After adding psychological distress symptoms, however, the influence of comor-
bidities lacked statistical significance. Symptoms of depression (OR .) and anxiety
(OR .) were the only factors significantly associated with high levels of fatigue.
Logistic regression analysis of the QLQ-C fatigue data did not differ from the
FAS data (data not shown). Using the QLQ-C having one to two comorbidities
(OR .,  CI .-., p=.) and symptoms of depression (OR .,  CI .-
., p=.) were the only variables associated with fatigue.
Discussion
In this cross-sectional study, we found a higher prevalence rate of fatigue in HL sur-
vivors compared with an age- and sex-matched Dutch normative population of 
and  using two different validated fatigue measures (QLQ-C fatigue and FAS
respectively).We also observed a significant association between fatigue caseness and
high levels of depression and anxiety, especially in the HL cohort. Mean fatigue levels
were significantly increased in theHL survivors comparedwith the norm population,
and differences were also found to be clinically relevant. Symptoms of depression
and (to a lesser extent) anxiety and comorbidities were found to be the only variables
associated with long-lasting fatigue.
One of the strengths of our study is that we measured fatigue through both a
generic (QLQ-C) and a fatigue-specific (FAS) questionnaire. Both questionnaires
independently measured a significantly higher prevalence of fatigue in the HL sur-
vivors. We showed that the identification of fatigue cases between both question-
naires was consistent in  of the HL survivors and  of the norm population.
Our data are robust, since missing items were < than .
Our study not only showes that HL survivors more often suffer from chronic
fatigue but also clearly shows an association between fatigue and depression or anx-






































































































































































































































































































































































































































































































































































































































































all HL survivors and of fatigue and depression in , compared with  and ,
respectively, in the norm population. is significant association between fatigue
and anxiety and depression has also been described by Loge et al. (). ey reported
high HADS scores (anxiety and depression combined) in  of  fatigued HL
survivors. eir results, however, were not compared with a control group or to a
norm population. Our study further showed that almost all () HL survivors with
symptoms of depression were also fatigued. As both studies were cross-sectional by
design, it is difficult to evaluate whether fatigue and anxiety or depression are two
separate entities both occurring more often in HL survivors, or whether fatigue is a
consequence of these psychological conditions.e lower level of cognitive function-
ing that we observed among the HL survivors, reflected in symptoms such as loss of
concentration, might be explained as a manifestation of the impact of fatigue and/or
psychological distress. In our multivariate analysis, we showed that depression and,
to a lesser extent, anxiety were significantly associated with fatigue. However, due
to the design of our study, a causal relation between fatigue, anxiety and depression
cannot be established.
In daily practice, fatigue in HL survivors has proven to be a prominent problem.
Many survivors report to suffer from chronic fatigue, with often significant impact on
daily activities, which has proven extremely difficult to treat. Studies evaluating inter-
ventions aimed at improvement of fatigue in cancer survivors have often shown im-
provement in physical endurance, but limited improvement in the subjective feeling
of fatigue and lack of energy (). Two recent meta-analyses concluded that exercise
interventions in fatigued cancer patients had a near-moderate effect size in reducing
fatigue at best (, ). Increased awareness of fatigue and of depression and anxiety
among treating physicians is essential. However, fatigue is more common and need
not be a symptom of depression or anxiety. Differentiating between these symptoms
can be challenging in the clinical setting. A possible aid in defining depression could
be to shift the focus from fatigue to other dimensions of depression. Symptoms of
depression and anxiety could be amenable to treatment. Psychosocial therapies such
as cognitive behavioral therapy or educational counseling have proven to be beneficial
in reducing symptoms of anxiety and depression ().
Itmight be beneficial for both patients suffering from fatigue and for patients with
depression or anxiety to receive treatment by professionals, although through dif-
ferent methods of focused psychosocial support or specific coping strategies, which
might result in a clinically meaningful reduction of fatigue. is approach, however,
should be explored in future studies. Ideally, HL survivors suffering from chronic
fatigue should be invited for a diagnostic interview to distinguish between fatigue
and depression, and then randomly assigned to specific psychosocial therapies. As
HL survivors are at risk for a variety of comorbid conditions due to late treatment
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sequelae, such as cardiovascular diseases, which could predispose for higher levels
of fatigue, we examined the possible association of fatigue and comorbid conditions
(, ). Hodgkin lymphoma survivors self-reported depression more frequently than
the norm population. Our multivariate analysis showed a trend for the association
between self-reported comorbidities and fatigue. However, mean time since diagno-
sis and treatment in this survey was still relatively short (mean . years, range  –
 months), which means that the majority of the cohort is not yet at risk for late
treatment sequelae. Moreover, with a mean age of  years, a large part of both the
cohort and the norm population would not yet suffer from serious comorbidities.
Rates of fatigue in HL survivors in this study ( by using QLQ-C and 
by using FAS) are slightly higher than the rates reported by others (, , ). ese
three studies reported fatigue rates of - in HL survivors, but all used the same
HL cohort. More recent data on cancer-related fatigue in patients with other types of
cancer using the EORTCQLQ-C andMultidimensional Fatigue Inventory showed
prevalence rates of  to , which are comparable to our results (-).
In conclusion, our results show a clinically relevant higher prevalence rate of
fatigue in HL survivors when compared with an age- and sex- matched population.
We also found a significant association between fatigue and anxiety or depression.
e only factors significantly associated with high levels of fatigue were symptoms of
depression and anxiety.is might have implications for the diagnosis and treatment
of fatigue in the clinical setting, as psychosocial therapies have proven to be effective
in reducing anxiety and depression, and could therefore be beneficial in reducing
levels of fatigue as well. is should be further examined in future trials.
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chapter 7
General discussion and future perspectives
In this thesis long-term sequelae that Hodgkin lymphoma (HL) survivors may
encounter have been investigated. Although modern treatment strategies have made
HL a highly curable disease, there is a life-long increased risk of morbidity and mor-
tality due to treatment. e diversity of these potential long-term adverse events
highlights the wide spectrum of possible treatment-related toxicities HL survivors
face after initial diagnosis and treatment. Both treatment with chemotherapy and
radiotherapy increase the risk of secondary cancers. Epidemiological studies have
shown that radiotherapy increases the relative risk of solid tumors, especially in pa-
tients treated at a young age, with a high total dose of radiotherapy or with large
radiation fields (). Risks progress from - years after initial treatment (). e
most common second malignancy is breast cancer in female HL survivors. Current
follow-up guidelines recommend screening of patients at risk for developing radia-
tion induced breast cancer.
Apart from second malignancies, HL survivors treated with mediastinal radio-
therapy also have increased risk of late cardiac complications (, ). A wide spectrum
of cardiovascular disease (CVD) can occur. In screening studies valvular disease, such
as calcification or retraction, is observed in - of patients (, ). Also, conduction
disorders due to fibrosis or direct damage to the conduction system have been fre-
quently described. e relative risk of myocardial infarction in HL survivors is -fold
increased, which might be due to radiation-induced coronary artery stenosis ().
All these adverse effects can severely impact health-related quality of life (HRQL).
epresence of long-termpsychosocial issues, fatigue or lack of energymay cause ad-
ditional deterioration of HRQL. e mechanism of persisting fatigue in HL survivors
is complex and believed to be multifactorial (). Patient- or treatment characteristics
associated with fatigue or not well defined, and treating psychosocial symptoms such
as fatigue, lack of energy or vitality have proven to be a clinical challenge.








An increased risk of treatment-related secondary tumors in HL survivors has been
established in numerous epidemiological studies. A detailed overview of the risk of
developing a second tumor was presented in chapter . e standardized incidence
ratio (SIR) of secondary tumors in HL survivors compared to the general population
ranges from - for different types of tumors. e risk of secondary skin cancers in
HL survivors has not been extensively studied. In chapter  we assessed the risk of
secondary skin cancers in a large cohort of HL survivors treated at Leiden University
Medical Center (LUMC). Skin cancers, and basal cell carcinoma (BCC) in particular,
are the most common types of cancer in the general population in the Netherlands.
To be able to compare risks established in our cohort with the general population
we used data from the Comprehensive Cancer Centre South registration, as BCC are
not registered in the Dutch Cancer Registry. We found an increased SIR of . for
BCC in HL survivors compared to the general population. Our results complement
the limited knowledge that existed concerning secondary-induced skin cancers inHL
survivors.
e SIR is a measure of expressing the relative risk of developing a second cancer,
compared to the general population. However, relative risks do not provide informa-
tion on absolute numbers of additional cases of cancer and thus clinical relevance and
burden of disease. is is better reflected in the absolute excess risk (AER), which
is a way of defining the difference in absolute risks of second cancers compared to
the general population. e AER expresses the number of additional second tumors
on top of the number expected in the general population. BCC is a type of tumor
frequently seen in the general Dutch population and incidence increases with older
age. e absolute number of BCC in the general population is therefore high and an
increased relative risk will result in a significant number of additional skin cancers;
this is reflected in a strongly increased AER: the number of excess cases of BCC in
HL survivors who are more than  years after initial treatment is more than  per
. patients per year. Comparison of our results to existing literature is difficult,
since data on secondary skin cancers in HL patients is limited. Swerdlow et al. ()
have reported risks of non-melanoma skin cancers (NMSC) in a large cohort of 
HL survivors treated between  and , of whom  were < years old at
time of diagnosis. ey report an overall SIR of . , which is lower than the rate that
was found in our cohort but might be explained by the shorter mean follow-up time.
Watt et al. () conducted a case-control study to evaluate the association between
radiation dose on the skin and occurrence of NMSC. Cases were selected from a large
cohort of childhood cancer survivors;  caseswere identified ofwhich wereHL
survivors, treated before the age of  years. A significant dose-response relationship
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was found; odd-ratios (OR) for developing NMSC increased from . at a skin dose
of  to  Gy up to an OR of  at a skin dose of - Gy. ese OR are much higher
than the rates that were found in our study, but patient characteristics between the
two cohorts were very different, as the childhood cohort only included patients who
completed treatment before the age of  years. In our study we have shown that age
at diagnosis is one of the most important factors in the risk of developing BCC.
BCC is a highly curable type of cancer. However, with larger tumors the risk of
morbidity due to treatment interventions and even mortality increases. Increased
awareness of the risk of secondary skin cancers both in patients but also in (treating)
physicians is essential for early detection and treatment. is might be achieved by
improving education on possible risks due to HL treatment in the setting of con-
tinuing training of physicians. Patients should be educated at the outpatient clinic
and instructed to examine the skin for lesions, especially at the location of previous
radiation treatment fields. Furthermore, the use of general preventative measures for
the development of skin cancer such as reducing sun exposure and use of protective
clothing and sun lotions are essential, and should be extensively discussed.
It is expected that risk of skin cancer for future HL patients will abate, due to the
decreased skin exposure with the currently used smaller radiation treatment fields.
On the other hand, for patients who have been treated with large radiotherapy fields
in the past the total number of skin cancers is expected to further increase in the
upcoming years due to increasing absolute risks with older age, thus implicating a
substantial and clinically relevant issue.
Cardiovascular disease and screening
Over the past decade increasing evidence for an increased risk of CVD in HL sur-
vivors has been collected from epidemiological studies. Moreover, CVD accounts for
major morbidity and is the most common nonmalignant cause of death at a relatively
young age in HL survivors. Risks of myocardial infarction due to coronary artery
disease (CAD) are - fold increased, with mediastinal radiation treatment as one
of the most predominant risk factors for developing CAD (, ). Previous studies
have shown that the course of CAD in HL survivors is often asymptomatic, even in
the presence of severe coronary stenosis, which has fuelled the interest in the role
of screening for CAD. Results from the first screening studies were disappointing,
mainly because of low sensitivity and specificity rates of the screening instruments
such as exercise stress testing (). Golden standard for the diagnosis of CAD and
its severity is invasive coronary angiography which is associated with a risk, albeit







small, of serious complications and even mortality and therefore deemed unsuitable
for the purpose of screening. A more promising screening modality is the computed
tomography coronary angiography (CTA). In symptomatic patients with an interme-
diate to high risk for CAD this non-invasive test has shown high diagnostic accuracy
(, ). A limited number of screening studies with CTA in Hodgkin lymphoma
survivors has been conducted. A small study consisting of  HL survivors showed
high rates of CAD (). Results however were confounded due to presence of cardiac
risk factors in almost all patients. A larger study among  childhood HL survivors
also reported a high rate of CAD on CTA ()(). In this study only  of the
participantswere treatedwithmediastinal radiotherapy as part of their treatment and
evaluation was done after a relative short follow-up period of  years. As themajority
of abnormalities on CTA were non-significant stenosis, most patients did not receive
further diagnostic interventions to confirm CTA results. Only  of participants
with abnormalCTAscans underwent subsequent invasive coronary angiography, and
a therapeutic intervention was performed in  patient.
Evidence for the role of CTA as a screening modality therefore remained limited
and was further evaluated in our screening study among  HL survivors (chapter
). In this phase II study participants underwent an extensive screening protocol, in
which not only the role of screening bymeans of CTAwas evaluated, but results were
also related to screening by means of ECG exercise testing. Furthermore, patients
with significant CAD on CTA subsequently underwent invasive coronary angiogra-
phy to confirm CTA results and, if indicated, to undergo therapeutic interventions.
In our study, we selected patients at a high risk of coronary abnormalities to evaluate
the use of CTA as a screening modality, based on time since diagnosis and treatment
with mediastinal radiotherapy. Of the  included patients,  had an evaluable CTA
scan. Of these patients,  had significant CAD (> narrowing) on CTA, and
another  had a non-significant stenosis with a lumen narrowing of -. is
rate of abnormal CTA scans is higher than the rate found in childhood HL survivors
by Küpeli et al. (), which could be explained by differences in patient and initial
treatment characteristics between the study populations, as in our study all patients
had been treated with mediastinal radiotherapy and screening was performed after a
significantly longer follow-up period. Significant coronary stenosis was verified by
means of invasive coronary angiography in all but one patient with an abnormal
CTA. In  () out of our  patients who underwent coronary angiography (CAG)
therapeutic interventions followed, in the majority of cases by means of revascu-
larization with percutaneous coronary intervention (PCI) or coronary artery bypass
graft (CABG). A small proportion was started on medical therapy. e intervention
rate in our study was also higher than intervention rates in other screening studies,
which again might be explained by differences in study population characteristics.
Recently, Girinsky et al. reported the outcome of their CTA screening study among
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 asymptomatic HL survivors, all of whom who had been treated with mediastinal
radiotherapy (). In their analysis  were diagnosed with coronary artery lumen
narrowing, ofwhich was intermediate or severe.Half of these patients underwent
diagnostic angiography and a total of  eventually underwent a therapeutic surgical
intervention. Again, these rates are lower than the  lumen narrowing and  of
surgical interventions in our cohort, but the median interval between treatment and
CTA in the study by Girinskyi was . years (range .-) compared to the longer
interval of  years (range -) in our study.
When relating CTA findings to the results of ECG stress testing, we found that
these results did not correspond. In only one patient with an abnormal CTA scan the
ECG stress test showed ischemia. None of the participants had typical symptoms of
ischemia, such as anginal complaints, during stress testing. ese findings confirm
that ECG stress testing only visualizes distinct ischemia, while CTA is able to de-
tect subclinical damage not (yet) resulting in detectable ischemia. A screening study
among HL survivors using ECGstress testing and radionuclide perfusion imaging
showed that during a median follow-up period of . years after finishing screening
 developed symptomatic coronary artery disease and  were diagnosed with a
cardiac event, including  cardiac deaths ().ese results underline the fact that
screening by means of ECG stress testing is not adequate in this population who do
not present with typical and early signs of ischemia and thus should not be used as a
screening modality.
Another possible screening modality would be the use of magnetic resonance
imaging (MRI). No screening studies using MRI have been performed in HL sur-
vivors. However, several studies have been conducted to establish the role of MRI in
detecting CAD in symptomatic patients, and therefore with a high disease prevalence
(>). A meta-analysis of these studies has shown high sensitivity and specificity
rates of CADdetectionwithMRI, although results vary considerably between studies
(). One of the advantages of screening by means of MRI is avoidance of ionizing
radiation. However, the most promising aspect of MRI screening is the ability to
visualize cardiac valves and myocardial wall movements in one single diagnostic
test. Whether MRI is equally effective in a population with a low prevalence rate
of CAD is as yet unknown. Both CTA and MRI screening require administration
of medication to decrease the heart rate to optimise image quality and the use of
intravenous contrast. In addition, MRI is an expensive diagnostic test, and relatively
burdensome for patients due to the noise and long duration of image acquisition.
At present, screening by means of CTA seems to be the most effective modality for
screening, with respect to a high diagnostic accuracy even for detecting subclinical
disease, cost-effectiveness and patient burden.
An essential prerequisite for justifying screening is that effective treatment for







screen-detected CAD is available. Ideally, detection and treatment of subclinical
coronary artery stenosis should lead to a decrease inmyocardial ischemia and infarc-
tion and thus to a decrease in the risk of cardiac morbidity and mortality. Since the
development of subclinical disease into clinically apparent ischemia or myocardial
infarction is uncertain and could possibly take years, this makes symptomatic cardiac
disease a difficult endpoint to assess in a clinical study, especially in a relatively small
population such as HL survivors. In our study no randomization between screening
and no screening was performed, since we determined this to be unethical. Neither
do we have long-term follow-up data of participants at present and therefore no
information on occurrence of cardiac events after screening. Moreover, none of the
other screening studies using CTA have reported on events after screening. Based
on our current results we can therefore not assess the clinical benefits of screening
and interventions in our asymptomatic population. However, a parallel can be drawn
with results from cardiologic studies. In asymptomatic cardiac populations an over-
all survival benefit has been shown in patients with severe proximal left CAD who
underwent subsequent interventions (, ). In our study population the majority
of coronary stenoses were located in the ostium or proximal in the main coronary
arteries, resulting in a large proportion of the heart at risk in the event of an occlu-
sion. Among the patients with significant CAD on CTA who underwent subsequent
invasive coronary angiography, two patients were diagnosed with severe main stem
stenosis of >. Complete occlusion of the main stem would result in absence of
blood flow to the entire heart. Our two patients with this severe occlusion reported
no cardiac symptoms, not even during adequate stress testing.e high prevalence of
proximal stenoses combined with the absence of accompanying warning symptoms,
and overall survival benefits of treating such lesions shown in cardiac populations
support the idea of screening in HL survivors.
However, screening has several potential disadvantages. Although the additional
radiation exposure due to CTA is considered low (- mSv) the tissue that is exposed
is mainly breast tissue which often is already at risk of developing secondary breast
cancer, especially in females. Also, diagnostic coronary angiography, performed to
confirm CTA results, can cause serious complications. Based on our first results and
the results from Girinsky et al. we can conclude that a population of asymptomatic
HL survivors, more than  years after treatment with mediastinal radiotherapy, in-
deed has a substantial risk of about  of significant CAD on CTA, and approxi-
mately - will need therapeutic surgical interventions. However, this means that
in the setting of screening  will not show any important abnormalities, but are
exposed to the potential risks and burden of screening. Ideally, we would need to
identify a high-risk subgroup within our HL survivor cohort, who are most at risk of
developing CAD. However, the included number of patients was too small to be able
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to identify a subgroup with the highest risk of abnormalities, such as those with other
risk factors, longer time since treatment or treatment parameters such as specific
location and dose of radiation fields. Girinsky et al. performed amultivariate analysis
and showed that age < years at diagnosis, other cardiovascular risk factors such
as hypertension or hypercholesterolemia but especially the dose at the origin of the
coronary arteries were prognostic predictors for the prevalence of coronary artery
stenosis ().
Apart from selection for screening based onpatient and treatment characteristics,
recent interest has focused on the role of selection based on cardiac biomarkers. A
wide range of markers has become available in recent years and are routinely used
in the diagnostic setting in patients presenting with symptomatic CAD. One of the
best known biomarkers is a hormone synthesized in the myocardium involved in the
sodium and water balance; B-type natriuretic peptide (BNP). Release of BNP occurs
in response to myocardial stretch, so it is said to be a measure of overall cardiac
function. It is most easily measured in the form of N-terminal pro-BNP (NTpro-
BNP), since this is a very stable molecule (). Several studies have investigated the
predictive role ofNTpro-BNP in absence of symptomatic cardiac disease (). Results
however are conflicting. Some studies show a predictive value of NTpro-BNP for the
risk of heart failure or major cardiovascular disease, others have failed to show a
predictive value for coronary artery disease-related death. Based on these results, pa-
tient selection for screening solely on biomarkers cannot be recommended at present.
Whether biomarkers will have additional value on top of selection for screening by
CTA based on patient and treatment characteristics should be explored in clinical
studies.
Other important aspects in the decision on whether or not to screen are cost-
effectiveness, compliance and the evaluation of the perceived burden and benefits
of screening. None of these aspects were evaluated in previous screening studies. In
our pilot study, we did evaluate the perceived burden and benefits of screening and
the influence of an extensive screening programme on health-related quality of life.
We also assessed the influence of extensive counseling on CVD and screening on
perceived information provision (chapter ). Counseling and screening emphasize
the possibility of serious, potentially life-threatening long-term complications of past
treatments. We have shown that a confrontation with these risks, the anxiety this
may cause and the psychological impact this may have, do not reduce the motivation
of patients to participate in a screening programme. In general, the counseling on
late treatment sequelae and screening tests were perceived as highly informative.
is resulted in a significantly and clinically relevant improvement in satisfaction
with information provision. e vast majority of patients were content with partici-
pating in the study. Although patients with screen detected abnormalities reported







the emphasis placed on late effects to be more burdensome than patients without
abnormalities, there was no difference in satisfaction in participating in screening.
All in all, the question whether or not to screen has not been completely an-
swered yet. We showed that for most patients, the perceived benefits of screening
outweigh the burden of screening, and that patient satisfaction strongly increases
with increased information provision on risk of late cardiac complications. However,
the greatest challenge lies in an optimal patient selection for screening. Although
CTA seems to be a sensitive and acceptable screening tool, current patient selection
based on mediastinal radiotherapy and time since treatment results in prevalence
of CAD on CTA of  and surgical interventions in , thus exposing  of the
selected patients to potential risks of screening, and  to potential risks of diagnostic
angiography. Before deciding for screening in a standard fashion, further refinement
of patient selection with factors such as radiation dose to the coronary arteries or
additional cardiac risk factors such as hypertension, should be done preferably based
on results from a larger scale cohort study, as is it unlikely that a randomised trials is
feasible in this population. At present this is being implemented at the LUMC as part
of the dedicated late effects outpatient clinic, and will probably be extended to other
hospitals participating in the nationwide network of long-term HL follow-up clinics
in the near future.
For all patients who are at risk of developing CAD, one of themost important pre-
ventive measures lies in patient education and control of cardiac risk factors. Many
patients, especially those who are not in follow-up at a dedicated late effects clinic,
are not aware of the magnitude of the risk of cardiovascular events due to their past
treatment. Patient awareness and lifestyle measures such as a healthy diet, adequate
physical activity and refraining from smoking are extremely important. With the
additional irreversible risk factor for CVD in the form of past mediastinal radiation
therapy it is of utmost importance to avoid all other cardiac risk factors as much as
possible.
Health-related quality of life and fatigue
Historically, interest for late effects of treatment in the follow-up of HL survivors has
been focused on the physical complications of treatment. However, in the past two
decades increasing interest and understanding of the psychosomatic and psychoso-
cial aspects of treatment and the burden of having survived cancer have developed.
As HL is a disease that predominantly affects young adults the diagnosis, treatment
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among children with cancer, the specific 
drugs and treatment modalities that were 
used in early clinical trials are still included 
in contemporary treatment protocols22,23. 
Initial paediatric-focused cancer therapy 
trials aimed to prevent developmental 
toxicities from affecting physical and intell-
ectual growth and development. Subsequent 
progress in cancer biology and therapeutics 
has resulted in greater numbers of survivors 
living into adulthood and has facilitated the 
appreciation of the increased risk of organ 
dysfunction and secondary carcinogenesis in 
ageing survivors. These findings collectively 
stimulated a reassessment of the short- and 
long-term gains that are associated with the 
use of intensive multimodality therapy in 
young people, and this produced paradigm 
shifts in the management of many paediatric 
cancers. For example, cranial irradiation 
was once lauded for its effectiveness in treat-
ing and preventing central nervous system 
disease in children with acute lymphoblastic 
leukaemia, but its use in frontline treatment 
protocols is now limited101. In the case of 
paediatric Hodgkin’s lymphoma treatment, 
doses of anthracyclines, as well as the fields 
and volumes of chest irradiation are proac-
tively restricted to decrease the risk of both 
cardiovascular injury and the development 
of subsequent neoplasms — especially breast 
cancer among female survivors102.
These and similar modifications that 
have been undertaken for other paediatric 
malignancies have reduced the occurrence 
of life-threatening complications that pre-
sent during childhood and adolescence, but 
their effects on ageing adults have not been 
established. However, as outlined above, 
contemporary therapy is still associated 
with many life-altering toxicities that affect 
neurocognitive, neurosensory, endocrine 
and reproductive function8–10. Pre-emptive 
screening and surveillance of at-risk treat-
ment groups can facilitate the early detec-
tion of and timely intervention for these 
common late effects. In general, the clinical 
course of normal tissue injury during the 
paediatric, adolescent and young adult age 
range has been well-defined for many treat-
ments. However, further research is needed 
to improve our understanding of the effects 
of ageing on the health of adults who are 
treated for cancer during childhood (FIG. 4)
Psychosocial and quality-of-life outcomes
Long-term survivors of childhood and 
adolescent cancers are at risk of experienc-
ing various psychological and social out-
comes19,103–105, which may result in decreased 
overall quality of life. Studies of long-term 
survivors have investigated the prevalence  
of and risk factors associated with educa-
tional and occupational attainment106–109, 
access to health insurance110,111, probability 
of marriage112–114, depression, anxiety 
and somatic distress115–117, post-traumatic 
distress118,119, post-traumatic growth120, 
fatigue121–123 and pain124. To varying degrees, 
the study of cancer- and treatment-related 
factors has identified high-risk populations. 
However, only limited data are available that 
describe longitudinal changes, and predic-
tors of change, for the psychosocial func-
tioning of ageing survivors of childhood and 
adolescent cancer115,118.
Chronic health conditions, psychosocial 
sequelae and chronic symptoms may ulti-
mately reduce the quality of survival through 
their effect on health and functional status7–11. 
These outcomes can be substantially influ-
enced by the developmental age at the time 
of treatment, the presence of co-morbid 
conditions that precede cancer diagnosis, and 
the survivor’s access to remedial and preven-
tive services. For example, although younger 
paediatric patients have higher risks of neuro-
cognitive injury after central nervous system-
directed therapy61, adolescent and young 
adult cancer survivors have been identified 
as a group that is particularly vulnerable to 
adverse psychosocial outcomes11,125. To opti-
mize health outcomes across the age range of 
childhood cancer survivors, care providers 
should consider the effects of both medical 
and psychosocial sequelae on the general 
health, mental health and function that is 
appropriate for the developmental age of  
the survivor, and they should help to facilitate 
survivors’ access to remedial services.
Methodological and practical issues
A cancer survivor can be defined in various 
ways, which range from when the diagnosis 
is made to some post-diagnosis time point. 
From a vital statistics perspective, a cancer 
patient is considered to be a ‘survivor’ start-
ing at diagnosis, whereas researchers often 
use a ‘time from diagnosis’ definition, which 
might be selected on the basis of the specific 
research question that is being addressed; for 
example, large cohorts, such as the Childhood 
Cancer Survivor Study126 and the British 
Childhood Cancer Survivor Study127, have 
used 5 years from diagnosis, others have used 
3 years post-diagnosis128, and some, such 
as the Bone Marrow Transplant Survivor 
Cohort, have applied alternative criteria 
using survival of ≥2 years from the time of 
haemato poietic stem cell transplant10. The 
major implication of differing definitions 
directly relates to the generalizability of the 
results and conclusions that are obtained from 
a specific population. Thus, as the amount 
of literature increases, it is important to con-
sider how the source population was defined 
when describing the status and risk profiles 
for childhood cancer survivors. Beyond the 
definition of a cancer survivor, there are 
several research-related issues that need to 
be considered when interpreting the cancer 
survivorship literature, as these can all influ-
ence how results are interpreted and trans-
lated into clinical practice: the study design, 
source and eligibility criteria for the study 
population; the study sample size; partici-
pation rates; completeness of follow-up;  
Figure 2 | Range of health-related and quality-of-life outcomes among long-term survivors of 
childhood and adolescent cancers. This figure shows some of the issues that are faced by survivors 
of childhood and adolescent cancers. GI, gastrointestinal. 
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Figure 7.1: Range f health-r lated d quality of life outcomes among long-term surviv of childhood
and adolescent cancers (21).
and late effects of treatment potentially affect a wide spectrum of psychosocial issues
(Figure .).
Facing the diagnosis of cancer confronts these young adults with their mortality,
in an age per od where most you g adults never have to face such insecure issues
and anxiety. Undergoing treatment severely impacts their normal life, and may re-
quire absence from school, work or family responsibilities. After treatment, distress
concerning o going toxicities but also of late effects ca severely influence health-
related quality of life (HRQL). Chronic symptoms and emotional distress can result
in difficulties to participate i produc ive work en ironm nt and aff ct the possibility
to maintain normal social relationships. Studies have shown that - of cancer
survivors come to face such difficulties (). Young adulthood is a time period in
which personal autonomy and development of an individual identity is established.
is makes young adults especially vulnerable to insecurity, anxiety and emotional
distress (). e possible limitations in daily life, especially in comparison with
healthy peers can be difficult to copewith.Of all psychosocial problems affecting can-
cer survivors one the most equ ntly reported symptoms is fatigue (). Especially
in young adult survivors of cancer, such as HL survivors, fatigue severely impacts
HRQL. In fact, f all s mptoms that affect cancer p ients fatigue and lack of nergy
or vitality is reported to be most distressing (). Fatigue can be present at diagnosis,
worsen during treatment and often remains present after cure. e pathogenesis f
cancer-related fatigue is not well understood, and is assumed to be a multifactorial
process. Several studies have shown a dysregulation of inflammatory cytokines to be







associated with the presence of fatigue (, ). Increasing evidence demonstrates a
role for a genetic predisposition (). Other potential contributing factors are pres-
ence of physical symptoms such as pain or loss of appetite, tumor related factors such
as anaemia or electrolyte disturbances ().
e prevalence of persisting fatigue and predictors of fatigue inHL survivors have
been evaluated in several studies. A review of the results of these studies is presented
in this thesis (chapter ). e prevalence of fatigue in HL survivors ranges between
studies from  to , and is significantly increased when compared to prevalence
rates in age-matched healthy populations. Identification of clinical or treatment re-
lated factors predisposing for persisting fatigue remains challenging. Studies often
encompass heterogeneous survivor cohorts, and longitudinal data aremostly lacking.
Furthermore, results often contradict, which makes it difficult to draw firm conclu-
sions. Our review showed that the only factor that systematically predicts persisting
fatigue throughout these studies is increasing age at diagnosis, and no impact of stage
of initial disease or treatment modality was shown. Only a few studies have evaluated
the association between fatigue and physical (treatment-induced) comorbidities or
psychiatric comorbid conditions. All of these studies showed increased prevalence
of fatigue in patients with comorbid conditions or psychiatric disorders, which can
be explained by the fact that these are also independent risk factors predicting fatigue.
e association between psychosocial distress and fatigue was addressed in only one
cross-sectional study, which showed that chronic fatigue and psychological distress
are two separate phenomena occurring in HL survivors, though they are correlated.
Unfortunately, results were not compared to a healthy norm population.
In chapter  the association between comorbidities and anxiety or depression
with fatigue was evaluated in patients recently treated for HL, and compared to data
from an age- and sex matched Dutch norm population. Our results confirmed the
increased prevalence of fatigue in HL survivors compared to the general population.
e rate of more than  HL survivors reporting fatigue is comparable to recent
fatigue data from survivors of other types of cancer. Our results confirm the asso-
ciation between fatigue and comorbidities. We also found a significant association
between the presence of anxiety and depression and prevalence of fatigue. To fully
comprehend the relation between these psychosomatic distress factors and fatigue
is challenging. First of all, the clinical distinction between fatigue as a single issue
and fatigue as part of a depression or anxiety disorder is often difficult to make,
because in most anxiety or depression scales the presence of fatigue is one of the key
aspects defining diagnosis. In the past decade there has been increasing awareness
and interest among physicians for psychosocial issues. For patients, the recognition
and acknowledgement of fatigue as a long-term complication of treatment has been
an important first step. e next step however, treating fatigue, has proven to be one
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of the most challenging problems in cancer care. Apart from cross-sectional studies
assessing the prevalence of fatigue in HL survivors, there have been very few studies
assessing the efficacy of different treatment strategies for fatigue. However, a parallel
might be drawn with other types of cancer. In breast cancer patients there have
been several studies evaluating the improvement of fatigue with physical exercise
treatment. ese studies often show improvement in physical endurance, but little
improvement in the subjective feeling of tiredness or lack of energy. For adult cancer
survivors psychosocial interventions such as cognitive behavioural therapies have
also been evaluated in randomized controlled trials. In a meta-analysis of these trials
a promising result was shown when interventions specifically focused on fatigue,
such as educational sessions and coping strategies (). e effect of such treatment
however was moderate, and long-term follow up data to confirm prolonged effect of
these interventions are needed. Especially in the setting of psychosocial interventions
differentiating between fatigue and psychological distress and other issuesmay prove
to be essential for optimizing further treatment strategies.
Conclusions
Awareness and recognition of long-term treatment related complications and prob-
lems have increased tremendously over the past decades, which has been an impor-
tant first step. Many issues however have not been resolved. Screening for secondary
malignancies, especially breast cancer has become standard of care. Awareness of
secondary skin cancers should be increased, as shown by our analysis. Evidence for
screening for cardiovascular disease, being the most common nonmalignant cause
of death in HL survivors, is increasing. Screening by means of CTA is feasible and
favourably evaluated, although further research is needed to optimize the selection
of patients who will benefit most. e psychosocial aspects of treatment influencing
quality of life have also gained increasing interest. Fatigue, as one of the most promi-
nent symptoms, is significantly increased in HL survivors, although predisposing
factors for persisting fatigue have been ill defined. Treating fatigue has proven to be a
clinical challenge, although a first approach should be in differentiating fatigue from
other psychosomatic distress factors. A personalized approach in which behavioural
therapies and educational sessions play a key role should be further explored.
In view of the emerging evidence of late treatment-induced toxicities in - of
HL survivors, the role of radiotherapy has been debated (, ). Several randomized








stageHL, in order to reduce late complications in futureHL survivors. A recentmeta-
analysis concluded that combined modality treatment is superior to treatment with
chemotherapy alone in terms of local control and short-term overall survival ().
Whether or not this gain in overall survival will persist over time remains to be seen,
due to the delayed morbidity and mortality of treatment related long-term toxicity.
It is likely that combined treatment of chemo- and radiotherapy is not necessary for
cure in all early stage HL survivors, and omission of radiotherapy may be possible
in a majority of this group. However, optimal selection of patients benefitting most
from combined treatment is essential. A first effort in selecting patients based on
interim PET-CT results was done in the subgroup of early stage HL with favourable
prognosis in the randomized EORTC H study. Recently, preliminary results of the
interim analysis of this patient tailored approach have been published (). ese
results were disappointing, showing an increase in local relapse in patients treated
with chemotherapy alone. Further research to establish which patient should and
should not be treated with combined modality treatment is needed.
For now, a large cohort of HL survivors exists who are at risk of late treatment
sequelae due to treatment received in the past. A large proportion of these patients
has been dismissed from follow-up clinics in the past, and might be unaware of po-
tential risks. Moreover, as HL is a relatively rare form of cancer, many general prac-
titioners and medical specialists who do not monitor HL survivors on a regular base
will also be unaware of potential risks. Education of these patients and physicians is
very important.e dedicated late effects outpatient clinics and its associated patient
information website are an effective method for educating survivors. In consultation
with patients an individual risk profile based on characteristics of previous treatment
can bemade, and from there a patient tailored survivorship care plan can be designed
and discussed with each individual HL survivor. Implementation of this care plan
can either be executed in the late treatment clinic, or in accordance with the treating
general practitioner. At Leiden University Medical Center (LUMC) we have estab-
lished the Hodgkin lymphoma late effects outpatient clinic in ; the “BETTER”
clinic. It was the first dedicated clinic in the Netherlands focusing on physical and
psychosocial aspects and complications of the treatment of HL and it was set up as
part of the nationwide network of dedicated specialists engaged in this subject. In the
near future, more of such clinics will be set up to ensure nationwide coverage. e
dedicated HL outpatient clinics thus provide the possibility to accurately monitor
future late effects. An essential aspect of these late treatment effect outpatient clinics
is that they provide a unique platform for future research, in order to continuously
optimise patient treatment and education.
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Summary
Chapter 1
Hodgkin lymphoma (HL) is a relatively rare haematological malignancy, predomi-
nantly affecting young adults. e outlook for cure for patients with HL is good, with
-year overall survival rates of  to  for all stages combined, and around  for
stages I-II. At present, treatment often consists of a combination of chemotherapy
and radiotherapy with limited treatment fields, especially in those presenting with
early stage disease. Over time it has become increasingly evident that the historically
used extensive treatment fields for HL can potentially lead to numerous long-term
adverse effects, often presenting clinically with a delay of more than - years after
treatment. Secondary tumours - such as breast cancer induced by radiotherapy and
non-Hodgkin lymphoma induced by chemotherapy - and cardiovascular diseases
are the best known long-term adverse events after HL treatment. However, cross-
sectional studies have also established long-term psychosocial and psychosomatic
symptoms in HL survivors, although predisposing factors and evidence-based treat-
ment options are still mostly lacking.
e objectives of this thesis were to address and investigate several late effects of
radiation therapy in HL survivors that have not been extensively studied:
. To evaluate the long-term risk of secondary skin cancers after radiother-
apy in HL survivors, and compare these risks to the general Dutch popu-
lation.
. To investigate the feasibility of screening for coronary artery disease by
means of computed tomography coronary angiography (CTA) in HL sur-
vivors, and evaluate satisfaction with information provision and the psy-
chological burden of screening.
Summary | 123
. To assess the prevalence of fatigue in HL survivors compared with the
general Dutch population, and evaluate associations with predisposing
factors.
Chapter 2
Increased rates of secondary solid tumours are seen after exposure to radiation ther-
apy. e evidence for the occurrence of secondary skin cancers in HL survivors is
limited, and was evaluated in a retrospective cohort study among  HL survivors
treated at LeidenUniversityMedical Center.e incidence of secondary skin cancers
following treatment for HLwas investigated in comparison to an age-matched Dutch
population, and the locations of the skin cancers were related to the radiation treat-
ment fields. A total of  skin cancers were diagnosed in thisHL cohort, themajority
() being basal cell carcinomas (BCC). e standardized incidence ratio (SIR, a
measure of relative risk) of BCC inHL survivorswas significantly increased compared
with the general population (SIR .,  confidence interval .-.), especially in
the group aged< years at diagnosis. Risks increasedwith longer follow-up; after 
years the SIR was ., resulting in  excess cases of BCC per . patients per
year. e majority of skin cancers developed within the radiation treatment fields
(). ese results confirm that radiotherapy for HL is associated with a strongly
increased long-term risk of developing skin cancers as compared with the general
Dutch population. Patients treated at a young age have the highest risk, which is in
accordance to incidence data from other types of radiation-induced solid tumours.
Since the absolute risk of developing skin cancer increases with age, the total number
of skin cancers is expected to rise even further with aging of our HL cohort, impli-
cating a substantial and clinically relevant future health issue.
Chapter 3
An increased risk of cardiovascular diseases, and especially a - fold increased risk
of myocardial infarction (MI) has been described in HL survivors, especially when
mediastinal radiotherapy was part of the treatment. e role of screening for coro-
nary artery disease (CAD), which could potentially lead to MI, is not well defined.
One of the most promising modalities for screening in terms of diagnostic accuracy
is the use of computed tomography coronary angiography (CTA), and feasibility of
screening using CTA was studied in a phase II study among  HL survivors who
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were at least  years after HL treatment. Participants underwent a comprehensive
screening protocol including ECG stress testing and CTA. Eventually,  CTA scans
were available for evaluation. Presence of CAD was evaluated and quantified. Pa-
tients with significant abnormalities underwent subsequent diagnostic testing and,
if indicated, intervention. A prevalence of significant coronary stenosis on CTA of
 (N=) was found, which is significantly increased to the expected prevalence in
the general population of  (p=.). A total of  patients underwent either invasive
(N=) or medical (N=) interventions. Results from exercise testing showed poor
correlation of ischemic changes to CTA findings. None of the participants suffered
anginal complaints during stress testing, and only one patient with significant CAD
on CTA had signs of ischemia during stress testing. Our results show a high preva-
lence of cardiac abnormalities, which were asymptomatic even in the presence of
life-threatening CAD. Although CTA seems a promising and feasible modality for
screening, before introducing CTA as standard screening of HL survivors, a larger
cohort study should be performed to confirm our results and to further refine patient
selection for screening.
Chapter 4
e results from our phase II study described in chapter  showed that cardiac
screening by CTA is feasible. However, confrontation of HL survivors with possible
cardiac diseasemay have a negative effect on psycho-social well-being.e perceived
burden and distress of undergoing CTA screening, and the effect of cardiovascular
counseling on perceived information provision are described in this chapter. In total,
 out the  patients from the phase II study also participated in this quality of life
evaluation and completed both baseline and end of study questionnaires. Undergoing
CTA was perceived as bothersome by  of the participants, and  felt nervous
about receiving the test results. Overall,  did not perceive the emphasis that was
placed on possible late cardiac effects of HL treatment by this screening study as
bothersome, and  were highly satisfied with participating in the study. ere
were no differences between patients with or without screen-detected abnormalities.
Perceived information on disease, medical tests and treatment increased significantly
after screening (p<.). Differences were clinically relevant. Screening by means of




Survivors of HL are at risk of adverse psychosocial or (psycho)somatic events as a
result of cancer diagnosis and treatment. Fatigue, often described as severe loss of
energy or loss of vitality is one the symptoms reported to interfere most frequently
with daily life. A systematic review of studies on prevalence and severity of fatigue,
and on predisposing factors for persisting fatigue was conducted. e majority of the
 included studies were of cross-sectional design, thus including heterogeneous pa-
tient populations and limiting the possibility to evaluate causal relationships between
fatigue and predisposing factors. Prevalence rates of fatigue were significantly higher
among HL survivors compared with the general population. In studies comparing
the severity of fatigue in HL survivors to an age- and sex matched norm population,
all but the two smallest studies reported statistically significant higher levels of fa-
tigue in HL survivors. Differences weremostly clinically relevant. None of the studies
showed an association between stage of disease at initial diagnosis and fatigue. Both
increasing age at diagnosis and the presence of comorbid conditions were associated
with risk of persisting fatigue. Evidence for the influence of other patient- or treat-
ment characteristics on persisting fatigue was often contradictory between studies,
preventing any firm conclusions concerning these factors.
Chapter 6
To investigate the prevalence and severity of fatigue in Dutch HL survivors we con-
ducted a study of health-related quality of life among  HL survivors.e response
rate was  and the mean follow-up duration was . years. Results were compared
to an age- and sex matched selection from a Dutch reference population cohort.
Furthermore, the association between fatigue and presence of anxiety and depression
was investigated. Fatiguewasmeasured both through a fatigue-specific questionnaire
(FAS) as well as part of a generic health-related quality of life questionnaire (EORTC
QLQ C-). Both questionnaires showed a statistically significant and clinically rel-
evant higher prevalence rate of fatigue in the HL cohort. e multivariate analysis
showed a strong and significant association between high levels of fatigue and de-
pression (odds ratio .,  confidence interval .-.) and was also associated
with anxiety and comorbidity (odds ratio .,  confidence interval .-. and
OR .,  CI .-. respectively). Treatment of fatigue has proven to be a clinical
challenge. e distinction between fatigue and symptoms of depression or anxiety
may prove to be beneficial in the clinical setting, since depression and anxiety may
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be amenable to psychosocial interventions such as cognitive behavioural therapies or
medication.
Chapter 7
In this chapter the main findings of this thesis are presented, and their implications
for adapting future follow-up strategies in order to improve after care for HL sur-
vivors are discussed and put into clinical perspective. HL survivors have an increased
risk of developing secondary skin cancers, especially basal cell carcinomas. e stan-
dardized incidence ratio (SIR) for this type of skin cancer is ., and even higher
relative risks are found in patients who were treated at an age younger than  years.
Along with increasing absolute risks with aging in general, the total number of skin
cancers in HL survivors is expected to increase even further in the coming years.
Although BCC is a curable type of cancer, early detection can prevent morbidity due
to extensive surgical interventions and even mortality. Increased awareness among
physicians and patients, and patient education with regard to preventative measures
and regular skin inspection is of utmost importance.
HL survivors are at risk of developing cardiac disease due to their treatment.
After mediastinal radiotherapy an increased risk of coronary artery disease (CAD)
is found. As the course of CAD is often asymptomatic, the question of screening
was raised. We have shown that the prevalence of screen-detected CAD by means of
CTA is high, with  significant CAD and  non-significant lumen narrowing in
 patients who had an evaluable CTA scan. e majority of patients with significant
disease () underwent subsequent intervention. Prevalence rates in our study are
higher than other screening studies, which is explained by our selection of high risk
patients, with a follow-up duration of more than  years. A health-related quality of
life assessment was conducted as part of our study, which demonstrated that for the
majority of patients the perceived benefits of screening outweighed the practical and
emotional burden. Although screening seems well tolerated and prevalence rates of
CAD on CTA are high, our current patient selection for screening would result in
a  rate of patients exposed to potential risks, costs and burden of screening, but
without significant abnormalities. is justifies further research, in order to identify
a subgroup of HL survivors who would benefit most from screening. Further future
refinement of patient selectionmight come from research identifying biomarkers, for
the risk of cardiac disease. A crucial role in decreasing the number of cardiovascular
events in HL survivors, lies in patient education and lifestyle measures, and control
of cardiac risk factors such as smoking, hypertension or diabetes.
Apart from the range of long-term physical complications HL survivors can de-
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velop over time, many of them also face long-term psychosocial and psychosomatic
events. One of symptoms that can greatly impact health-related quality of life is per-
sisting fatigue. In our systematic review we showed both prevalence and severity of
fatigue to be significantly higher in HL survivors than in the general population. e
identification of predisposing factors for fatigue is, unfortunately, often hampered by
study design.
For patients, acknowledgement of fatigue as a genuine long-term complication
has been an important first step. However, the challenge that remains is to find an
effective treatment for persisting fatigue. We showed a strong association between
fatigue and symptoms of anxiety and depression in HL survivors. e distinction
between these symptoms may offer a first beneficial treatment step, since anxiety
and depression might be amenable to psychosocial therapies.
Conclusions
In view of the emerging evidence of late treatment-induced toxicities in - of
HL survivors, the role of radiotherapy has been debated. As for now, studies have
shown superior local control and short-term overall survival when radiotherapy is
part of HL treatment. With the delay of - years until clinical presentation of
potential radiotherapy-induced morbidity and mortality is encountered it remains
to be seen whether these short-term benefits will translate in a long-term overall
survival benefit. It is likely that only a subgroup of patients benefits from the addition
of radiotherapy, although more research is needed to identify this group. e risk of
radiation induced late sequalae is expected to further decrease with the development
of new radiotherapy techniques and decreasing the total radiotherapy dose en fields.
For now however, there is a large group of HL survivors who are at risk of late
treatment sequelae, of whom a proportion remains unaware of potential risks. Iden-
tifying these patients and informing them of risks is important, and is currently being
done in the setting of specialised late effects outpatient clinics. Also, the patient and
health professional information website www.beternahodgkin.nl which has been de-
veloped by the late effects consortium ‘BETER’ is an easily accessible method for im-
proving information provision.e dedicated outpatient clinics furthermore provide
a unique possibility to monitor future late effects, and provide a research platform
for screening and interventions and to further develop evidence based follow-up




Het Hodgkinlymfoom (HL, lymfklierkanker van het Hodgkin-type) is een relatief
zeldzame hematologische maligniteit, die voornamelijk bij jongvolwassenen voor-
komt. De kans op genezing van HL is groot: de -jaarsoverleving ligt voor vroege
stadia (stadium I-II) rond de , en voor alle stadia samen tussen de  en .
De behandeling van patiënten met HL bestaat tegenwoordig vaak uit een combinatie
van chemotherapie en radiotherapiemet gebruik van relatief kleine bestralingsvelden
en gematigde dosis, vooral bij patiënten die zich presenteren met een vroeg ziekte-
stadium. In de loop van de afgelopen jaren is het duidelijk geworden dat de in het
verleden gegeven behandeling voor HL met zeer uitgebreide bestralingsvelden en
hogere dosis een groot aantal langetermijnproblemen tot gevolg kan hebben, die zich
vaak pas - jaar na behandeling presenteren. De meest bekende langetermijnge-
volgen zijn secundaire tumoren (zoals borstkanker geïnduceerd door behandeling
met radiotherapie of non-Hodgkinlymfoom door behandeling met chemotherapie)
en cardiovasculaire schade (zoals kransslagadervernauwing). Een aantal studies heeft
inmiddels ook aangetoond dat HL-overlevenden kunnen kampen met psychosoci-
ale en psychosomatische langetermijnproblemen, zoals chronische vermoeidheid,
angst en depressie, hoewel predisponerende factoren hiervoor niet duidelijk zijn en
evidence-based behandelopties tot op heden grotendeels ontbreken.
De doelstellingen van de studies in dit proefschrift waren om een aantal late ge-
volgen van radiotherapie bij overlevenden vanHL, die nog niet uitgebreid bestudeerd
zijn, in kaart te brengen; specifieke doelen waren:
. Na te gaan of het risico op geïnduceerde huidtumoren na radiotherapie bij
HL overlevenden verhoogd is, en hoe hoog deze risico’s zijn in vergelijking
met de algemene Nederlandse bevolking.
Nederlandse samenvatting | 131
. Na te gaan of screenen op vernauwing van coronairvaten door middel van
CT-coronair angiografie bij HL overlevenden zinvol is, en te evalueren hoe
de tevredenheid met de informatievoorziening rondom screening en de
psychologische belasting van screening zijn.
. Na te gaan hoe vaak chronische vermoeidheid onder HL-overlevenden
voorkomt in vergelijking met de algemene Nederlandse bevolking, en te
onderzoeken wat de predisponerende factoren zijn.
Hoofdstuk 2
Radiotherapie geeft een verhoogd risico op geïnduceerde solide tumoren, die optre-
den vanaf - jaar na de radiotherapie. Er is tot op heden weinig bekend over het
voorkomen van (mogelijk geïnduceerde) huidtumoren bij overlevenden van HL. In
een retrospectieve cohortstudie onder  HL-overlevenden die behandeld waren
in het Leids Universitair Medisch Centrum werd het voorkomen van huidtumoren
onderzocht. De incidentie van huidtumoren werd vergeleken met een voor de leef-
tijd gematchte Nederlandse populatie, en werd voor iedere patiënt gerelateerd aan
de eerdere bestralingsvelden. In dit cohort van  overlevenden van HL werden
in totaal  huidtumoren gediagnosticeerd, waarvan het merendeel () bestond
uit basaalcelcarcinomen (BCC). De standaard incidentie ratio (SIR) van BCC in HL-
overlevenden was significant (x) verhoogd in vergelijking met de gematchte alge-
mene bevolking (SIR .,  betrouwbaarheidsinterval .-.), vooral in de groep
overlevenden die bij diagnose HL jonger dan  jaar waren. Risico’s op BCC namen
toe met duur van follow-up; na  jaar was de SIR ., hetgeen resulteert in een
extra aantal gediagnosticeerde tumoren van  BCC’s per . patiënten per jaar.
Het merendeel van de huidtumoren ontwikkelde zich binnen de bestralingsvelden
(), en op aan zonlicht blootgestelde lichaamsdelen. De gevonden resultaten be-
vestigen dat radiotherapie, zoals gebruikt in de behandeling van HL, is geassocieerd
met een sterk verhoogd langetermijnrisico op het ontwikkelen van huidtumoren in
vergelijking met de algemene Nederlandse bevolking. Patiënten die op jonge leef-
tijd behandeld zijn lopen het grootste risico, hetgeen overeenkomt met het risico
op andere radiotherapie-geïnduceerde solide tumoren zoals borstkanker. Gezien het
feit dat het absolute risico op het ontwikkelen van huidkanker toeneemt bij ouder
worden, is de verwachting dat het totaal aantal huidtumoren in het HL cohort nog
sterk zal toenemen. Patiënten die in het verleden zijn behandeld voor HL en hun art-
sen moeten hierop alert zijn, zodat diagnostiek en behandeling in een vroeg stadium
kunnen plaatsvinden.
132 | Nederlandse samenvatting
Hoofdstuk 3
Bij langetermijnoverlevenden van HL wordt na bestraling van de lymfklieren in de
borstholte (mediastinale radiotherapie) een verhoogd risico op cardiovasculaire aan-
doeningen beschreven, met name een - keer verhoogd risico op een krijgen van
een myocardinfarct (MI) door kransslagadervernauwing. De rol van screenen op
vernauwing van de kransslagaders (coronair sclerose), hetgeenmeestal ten grondslag
ligt aan een MI, is nog niet goed omschreven. Een van de meest veelbelovende mo-
daliteiten om mee te screenen vanwege een hoge diagnostische accuraatheid, is het
gebruik van de CT-scan van de kransslagaderen (CTA). De haalbaarheid van scree-
ningmet behulp van CTAwerd onderzocht in een fase-II-studie met  ex-patiënten
die tenminste  jaar ziektevrij waren na hun behandeling voor HL. Deelnemers
aan de studie ondergingen een uitgebreide cardiologische screening, onder andere
bestaand uit een ECG-stresstest (fietsproef ) en een CTA. Uiteindelijk waren er 
CTA scans beschikbaar voor evaluatie. Aanwezigheid van kransslagadervernauwing
werd gescoord en patiënten met ernstige afwijkingen, gedefinieerd als een vernau-
wing van tenminste  van de doorsnede van de kransslagader, werden verwezen
voor aanvullend diagnostisch onderzoek en afhankelijk van de uitkomst daarvan voor
interventie. De prevalentie van ernstige kransslagadervernauwing op CTA was 
(N=), hetgeen significant hoger was dan de verwachte prevalentie van  in de
algemene bevolking van dezelfde leeftijd (p=.). In totaal ondergingen  patiënten
een chirurgische interventie (N=) of een medicamenteuze interventie (N=). De
correlatie tussen een afwijkende ECG-stresstest en een afwijkende CTA was laag.
Geen van de deelnemers kreeg tijdens de ECG-stresstest klachten van pijn op de
borst, en slechts één patiënt met significante coronair sclerose op CTA had tekenen
van ischemie tijdens de stresstest. Onze resultaten tonen een hoge prevalentie van
cardiale afwijkingen bij patiënten die in het verleden voor HL zijn behandeld en
die zelfs in de aanwezigheid van levensbedreigende kransslagadervernauwing geen
cardiale klachten aangaven. Ondanks het feit dat CTA een veelbelovende en goed
uitvoerbare modaliteit voor screening lijkt te zijn, moeten, voordat een dergelijke
screening definitief wordt ingevoerd, onze resultaten bevestigdworden in een grotere
cohortstudie.Ookmoet er gekekenworden of er een betere selectie vanHL-patiënten
voor wie CTA screening zinvol is kan worden gemaakt, door onderzoek te doen naar
sterkere risicofactoren.
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Hoofdstuk 4
De resultaten van de fase-II-studie beschreven in hoofdstuk  toonden dat cardiale
screening doormiddel van CTA goed uitvoerbaar is. Echter, de confrontatie met mo-
gelijke cardiale afwijkingen kan eennegatieve impact hebben ophet psychischwelzijn
van patiënten. De psychische en fysieke belasting van het ondergaan van een CTA, en
het effect van cardiovasculaire counseling op tevredenheid met informatievoorzie-
ning worden beschreven in hoofdstuk . In totaal deden  van de  deelnemers van
de fase-II-studie mee aan deze kwaliteit van leven evaluatie. Zij vulden zowel vooraf-
gaand als na afloop van het screeningstraject een aantal vragenlijsten in, die gericht
waren op informatievoorziening, kwaliteit van leven en de psychische belasting van
de confrontatie met de mogelijke cardiale risico’s. Het ondergaan van een CTA werd
door  van de deelnemers als belastend ervaren, en  was zenuwachtig voor
krijgen van de uitslagen van de scan. De nadruk die door het screeningsonderzoek
werd gelegd op mogelijke cardiale afwijkingen werd door  van de deelnemers als
niet belastend ervaren, en  was ook achteraf tevreden over meedoen aan het on-
derzoek. Er waren hierin geen verschillen tussen ex-patiënten met en patiënten zon-
der afwijkingen bij screening. De informatievoorziening met betrekking tot ziekte,
medische tests en behandeling en kennis daarvan waren significant verbeterd na af-
loop van het screeningstraject (p=.). Deze verschillenwaren ook klinisch relevant.
Screening door middel van CTA werd door de deelnemers positief gewaardeerd, en
de voordelen van screening wogen bij de grote meerderheid op tegen de emotionele
en praktische belasting.
Hoofdstuk 5
Mannen en vrouwendie in het verleden zijn behandeld voorHL lopen ten gevolge van
de diagnose en behandeling ook het risico blijvende psychosociale of psychosomati-
sche klachten te ontwikkelen. Vermoeidheid, ook wel beschreven als verlies van ener-
gie, het gevoel ‘dat de batterij leeg is’ of sterke lusteloosheid, is een van de symptomen
waarvan ex-HL-patiënten aangeven dat die de kwaliteit van het dagelijks leven het
meest beïnvloedt. Een systematische reviewwerd verricht van studiesmet betrekking
tot het voorkomen (prevalentie) en de mate van vermoeidheid, en van studies die
predisponerende factoren voor vermoeidheid analyseerden. De meerderheid van de
 geïncludeerde studies had een dwarsdoorsnede (cross-sectionele) opzet, hetgeen
betekent dat de patiënten die geïncludeerd waren onderling vaak veel verschilden,
waardoor een causaal verband tussen vermoeidheid en voorspellende factoren niet
goed te leggen was.
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De prevalentie van vermoeidheid onder HL-overlevenden was significant hoger
dan in de algemene populatie. Studies waarin de ernst van vermoeidheidklachten
onderHL-overlevenden vergelekenwerdmet qua leeftijd en geslacht gelijke groep uit
de algemene bevolking toonden, behoudens in de twee kleinste studies, een statistisch
significante zwaardere (ernstigere) vermoeidheid in de groep van HL-overlevenden.
De gevonden verschillen waren in de meeste studies ook klinisch relevant. Geen van
de studies toonde een associatie tussen het stadium van de ziekte bij diagnose en
vermoeidheid. Zowel een hogere leeftijd bij diagnose als de aanwezigheid van andere
aandoeningen (comorbiditeit) waren geassocieerd met een risico op chronische ver-
moeidheidsklachten. Resultaten met betrekking tot de invloed van andere patiënt-
of behandelkarakteristieken op blijvende en ernstige vermoeidheidsklachten waren
vaak tegenstrijdig, waardoor een harde conclusie omtrent deze factoren nietmogelijk
was.
Hoofdstuk 6
Het voorkomen en de ernst van blijvende vermoeidheid onder Nederlandse ex-
HL-patiënten werd onderzocht in een kwaliteit-van-leven-studie onder  HL-
overlevenden. Het responspercentage was  en de gemiddelde follow-up-duur na
de diagnoseHLwas . jaar. De resultatenwerden vergelekenmet een voor leeftijd en
geslacht gematchte selectie uit een Nederlands referentiecohort, representatief voor
de algemene bevolking. Ook werd gekeken naar de associatie tussen vermoeidheid
en symptomen van angst of depressie. Vermoeidheid werd gemeten door middel
van twee vragenlijsten, zowel een specifieke vragenlijst voor vermoeidheid (FAS)
als met een subschaal over vermoeidheid uit de algemene Europese kwaliteit-van-
leven-vragenlijst voor kanker (EORTC QLQ-C). Beide vragenlijsten toonden een
statistisch significante en klinisch relevante hogere prevalentie van vermoeidheid
in het cohort van HL-overlevenden. De verrichte multivariate analyse toonde een
sterk en significant verband tussen een hoger niveau van vermoeidheidsklachten en
symptomen van depressie (odds ratio .,  betrouwbaarheidsinterval .-.) en
een ook met symptomen van angst en met comorbiditeit (respectievelijk odds ratio
.,  betrouwbaarheidsinterval .-. en odds ratio .,  betrouwbaarheids-
interval .-.). In de klinische praktijk is chronische vermoeidheid een moeilijk te
behandelen symptoom gebleken. Mogelijk is het onderscheid tussen vermoeidheid
en symptomen van angst of depressie hierbij belangrijk, omdat angst en depressie te
behandelen zijn met psychosociale interventies zoals cognitieve gedragstherapie of
met medicijnen.
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Hoofdstuk 7
In dit hoofdstuk wordt een overzicht gegeven van de belangrijkste bevindingen van
dit proefschrift, en worden de implicaties hiervan voor verder onderzoek, begelei-
ding en voor follow-up-richtlijnen in perspectief geplaatst, om zo de nazorg voor
overlevenden van HL verder te verbeteren. HL-overlevenden hebben een verhoogd
risico op het ontwikkelen van een secundaire huidtumor, vooral basaalcelcarcinomen
(BCC).Het risico op het krijgen van eenBCC is x zo groot als voor een leeftijdgenoot
in de algemene bevolking, en dit relatieve risico ligt nog hoger voor patiënten die
behandeld zijn op een leeftijd onder de  jaar. Gezien het toenemend absoluut risico
op BCC met hogere leeftijd zal het totaal aantal huidtumoren dat voorkomt bij HL-
overlevenden naar verwachting nog verder stijgen. BCC is een goed te genezen vorm
van huidkanker, maar vroegtijdige ontdekking ervan kan ervoor zorgen dat de be-
handelingminder ingrijpend hoeft te zijn, en kan zelfs de kans op uiteindelijke sterfte
beperken. Bewustwording van deze risico’s bij artsen en patiënten, voorlichting met
betrekking tot preventieve maatregelen (vermindering van blootstelling aan de zon,
beschermende kleding e.d.) en regelmatige inspectie van de huid zijn daarom erg
belangrijk.
Overlevenden van HL hebben door hun behandeling ook een verhoogd risico
op het ontwikkelen van hart- en vaatziekten (HVZ). Omdat dit vaak geen of wei-
nig symptomen geeft, is de rol van screening op kransslagadervernauwing (coronair
sclerose) onderzocht. Onze studie, waarin de kransslagaderenwerden afgebeeld door
middel van een CT-scan van de kransslagaderen (CTA) toonde bij  van de pati-
ënten een ernstige vernauwing (meer dan  vernauwing) van de kransslagaderen.
Daarnaast werd bij  een niet-significante vernauwing (een vernauwing van het vat
van tussen de -) gezien. Het merendeel van patiënten met ernstige afwijkin-
gen () onderging daarna een behandeling. Ernstige afwijkingen werden in onze
studiegroep vaker gevonden dan in andere screeningsstudies, waarschijnlijk omdat
patiënten in onze studie een relatief hoog risico hadden, omdat zij tenminste  jaar
na behandeling moesten zijn om mee te mogen doen. Om na te gaan of het proces
van screenen en de nadruk die door screenen gelegd wordt op de kans op levensbe-
dreigende complicaties van de vroegereHL-behandeling als belastendwordt ervaren,
werd er een kwaliteit-van-leven-evaluatie gedaan als onderdeel van de screeningsstu-
die. Deze toonde aan dat voor hetmerendeel van de ex-patiënten de voordelen van de
kennis rond de risico’s en het screeningsonderzoek, waardoor meer zekerheid werd
gekregen opwogen tegen de praktische uitvoering en belasting van het ondergaan
van screening. Alhoewel screening weinig nadelige effecten had, en het voorkomen
van coronair sclerose hoog was, leidt de huidige selectie voor screening ertoe dat er
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in  van de gevallen geen belangrijke afwijkingen worden gevonden, terwijl deze
ex-patiënten wel de risico’s en belasting van screenen ondergaan. Verder onderzoek
lijkt dus geïndiceerd, om een subgroep van patiënten te kunnen identificeren die
de meeste baat van screening zal hebben. In de toekomst zal verdere verfijning van
patiëntselectie mogelijk kunnen plaatsvinden op basis van bepaling van biomarkers,
hoewel ermeer klinisch onderzoeknodig is omdeprognostischewaarde hiervan voor
het optreden van HVZ te bevestigen. Een cruciale rol in het voorkomen van HVZ
bij HL-overlevenden ligt in voorlichting met betrekking tot risico’s, aanpassingen
in leefstijl en controle op andere cardiale risicofactoren zoals roken, hypertensie of
diabetes.
Naast de lange-termijn fysieke complicaties die na behandeling van HL kunnen
optreden, kunnen patiënten ook lijden aan psychosociale en psychosomatische pro-
blemen. Een van de symptomen die een grote negatieve invloed heeft op de ervaren
kwaliteit van leven is chronische vermoeidheid. In onze systematische review hebben
we laten zien dat zowel het voorkomen van vermoeidheid als de ernst van vermoeid-
heidsklachten significant hoger is in de groep HL-overlevenden dan in de algemene
populatie. De identificatie van prognostische factoren wordt bemoeilijkt door onder-
zoeksopzet van veel studies. Voor veel patiënten is de erkenning van vermoeidheid als
een langetermijneffect van behandeling een belangrijke eerste stap geweest. Echter,
behandeling van vermoeidheidsklachten is in praktijk moeilijk gebleken. We hebben
aangetoond dat er een sterk verband bestaat tussen vermoeidheid en symptomen van
angst en depressie. Het onderscheid tussen deze symptomen is mogelijk een eerste
belangrijke stap, gezien het feit dat angst en depressie mogelijk te behandelen zijn
met psychosociale therapieën.
Conclusies
Ongeveer - van de ex-HL-patiënten ontwikkelt late behandelingsgerelateer-
de toxiciteit. Over de rol van radiotherapie in de behandeling van HL wordt veel
gediscussieerd. Tot op heden heeft onderzoek naar weglaten van radiotherapie als
onderdeel van de behandeling aangetoond dat met plaatselijke radiotherapie op de
oorspronkelijk aangedane gebieden bij vroeg stadiumHL de lokale controle en korte-
termijnoverleving superieur zijn ten opzichte van behandeling met alleen chemothe-
rapie. Omdat er tussen behandeling en het optreden van radiotherapie-geassocieerde
langetermijneffecten een interval van - jaar zit, is het onzeker of dit zich ook
vertaalt in een langetermijnoverlevingswinst. De verwachting is dat door verfijning
van de radiotherapietechnieken, het gebruik van een lagere radiotherapiedosis en veel
Nederlandse samenvatting | 137
minder uitgebreide radiotherapievelden voor de behandeling van Hodgkinlymfoom
het risico op het optreden van late effecten sterk zal afnemen.
Voor nu bestaat er echter een grote groep HL-overlevenden die risico lopen op
langetermijngevolgen van behandeling, waarvan een gedeelte niet op de hoogte is van
deze risico’s. Het identificeren van deze patiëntgroep en goede, op maat gemaakte
voorlichting is belangrijk, en wordt momenteel gedaan als onderdeel van het lande-
lijke consortium van late-effecten-poliklinieken. Dewebsite www.beternahodgkin.nl,
die is ontwikkeld door het ‘BETER’ consortium is een toegankelijke manier om voor-
lichting aan patiënten en hulpverleners te verbeteren. De late-effecten-poliklinieken
bieden daarnaast een uniekemogelijkheid om late effecten temonitoren, en bieden de
mogelijkheid om onderzoek te doen en evidence-based follow-up richtlijnen verder
te ontwikkelen voor deze groep patiënten.
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